Delaware |
26-2222607 |
|||||
---|---|---|---|---|---|---|
(State
or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
Paul D. Chestovich, Esq. Maslon Edelman Borman & Brand, LLP 3300 Wells Fargo Center 90 South Seventh Street Minneapolis, Minnesota 55402 Tel: (612) 672-8200 |
Copies to: GWG Holdings, Inc. Jon R. Sabes Chief Executive Officer 220 South Sixth Street, Suite 1200 Minneapolis, Minnesota 55402 Tel: (612) 746-1944 (Name, address, including zip code, and telephone number, including area code, of agent for service) |
James T. Seery, Esq. LeClairRyan One Riverfront Plaza 1037 Raymond Boulevard, 16th Floor Newark, New Jersey 07102 Tel: (973) 491-3315 |
---|
Large
accelerated filer o |
Accelerated filer o |
|||||
Non-accelerated filer o |
Smaller reporting company x |
|
|
|
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Title of each class of securities to be registered |
Amount to be registered(1) |
Proposed maximum offering price per share |
Proposed maximum aggregate offering price(2) |
Amount of registration fee(3) |
||||||||||||||
Common Stock,
$0.001 par value |
1,840,000 | $13.50 | $24,840,000 | $3,200 |
(1) |
Includes 240,000 shares purchasable by the underwriters to cover over-allotments, if any. |
(2) |
Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) of the Securities Act of 1933. |
(3) |
Filing fees in the amount of $1,932 were previously paid. |
Per Share |
Total |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Public
offering price |
$ | $ | ||||||||
Underwriting
commissions (1) |
$ | $ | ||||||||
Proceeds to
us, before expenses |
$ | $ |
(1) |
See Underwriting beginning on page 92 for disclosure regarding compensation, including reimbursement of expenses, payable by us to the underwriters. |
Page |
||||||
---|---|---|---|---|---|---|
1 | ||||||
2 | ||||||
10 | ||||||
12 | ||||||
28 | ||||||
29 | ||||||
30 | ||||||
31 | ||||||
32 | ||||||
48 | ||||||
72 | ||||||
79 | ||||||
81 | ||||||
82 | ||||||
84 | ||||||
86 | ||||||
87 | ||||||
91 | ||||||
93 | ||||||
96 | ||||||
96 | ||||||
96 | ||||||
F-1 |
would maintain monopsony power over the options offered to consumers who no longer need or want their life insurance.
Total
portfolio face value of policy benefits |
$ | 771,940,000 | ||||
Average face
value per policy |
$ | 2,699,000 | ||||
Average face
value per insured life |
$ | 3,015,000 | ||||
Average age
of insured (yrs.) * |
82.3 | |||||
Average life
expectancy estimate (yrs.) * |
7.02 | |||||
Total number
of policies |
286 | |||||
Number of
unique lives |
256 | |||||
Demographics
|
67% Males; 33% Females |
|||||
Number of
smokers |
3 insureds are smokers |
|||||
Largest
policy as % of total portfolio |
1.30 | % | ||||
Average
policy as % of total portfolio |
0.35 | % | ||||
Average
Annual Premium as % of face value |
3.15 | % |
premiums expected to be paid over the life of the insured; (iv) market competition from other purchasers in the secondary market; and (v) the particular underwriting characteristics of the policy, relative to the characteristics of our portfolio of life insurance assets as a whole.
|
Industry Experience: We have actively participated in the development of the secondary market of life insurance as a principal purchaser and financier within the asset class since 2006. Our position within the marketplace has allowed us to gain a deep understanding of the life insurance secondary market. We have participated in the leadership of various industry associations and forums, including the Life Insurance Settlement Association (LISA) and the Insurance Studies Institute (ISI). Our experience gives us confidence in building a company to compete in the industry and acquire a portfolio of life insurance policies that will perform to our expectations. |
|
Operational Platform: We have built and continue to refine and develop an operational platform and systems for efficiently tracking, processing, and servicing life insurance policies that we believe provide competitive advantages when participating in the life insurance secondary marketplace. |
|
Origination and Underwriting Practices: We seek to use underwriting review processes and file documentation standards that generally meet published guidelines for rated securitizations of life insurance portfolios. We purchase life insurance policies we consider to be non-contestable and that meet our underwriting criteria and reviews. We consider a life insurance policy to be non-contestable once applicable state law prohibits the insurer from challenging the validity of the policy due to fraud. In this regard, state non-contestability laws generally require a period of one to two years to elapse after the initial issuance of the policy before that policy is considered non-contestable under state law. Non-contestability laws do not, however, prevent an insurer from challenging the validity of a policy procured by fraud for lack of an insurable interest at the time at which the policy was purchased, such as is the case with so-called stranger-originated life insurance policies. To the extent we use modified methodologies for estimating life expectancies for small face policies, those modified methodologies may not meet published guidelines for rated securitizations of life insurance portfolios. |
|
Origination Relationships and Strategies: We have established origination relationships with life insurance policy brokers and insurance agents who submit policies for our purchase or financing. Our referral base knows our underwriting standards for purchasing life insurance policies in the secondary market, which provides confidence in our bidding and closing processes and streamlines our own due-diligence process. We expect to expand our origination methodology and channels with the proceeds of this offering (e.g., the addition of consumer marketing). |
|
Life Expectancy Methodology: We generally rely on two life expectancy estimates obtained from independent third-party medical-actuarial underwriting firms to arrive at a life expectancy estimate we use for valuing a life insurance asset. For a majority of our life insurance asset purchases, we rely on estimates obtained from 21st Services and AVS Underwriting to develop our life expectancy estimate. We may, however, also obtain and use life expectancy estimates from other medical-actuarial underwriting firms. As explained above, we may from time to time modify our underwriting review processes, including our methodology for arriving at life expectancy estimates we use in ascribing value to a life insurance asset. |
|
Pricing Software and Methodology: To calculate our expected returns on the investments we make in life insurance assets, we use actuarial pricing methodologies and software tools built by a leading independent actuarial service firm and currently supported by Modeling Actuarial Pricing Systems, Inc. (MAPS). |
|
Financing Strategy: We have actively developed diversified financing strategy for accessing capital markets in support of our buy-and-hold strategy for our portfolio of life insurance policies, ranging from institutional bank financing to a network of broker-dealers registered with the Financial Industry Regulatory Authority (FINRA), many of whom have participated in one or more of our Series I Secured note financing, our Series A preferred stock financing, or our Renewable Secured Debenture financing. If in the future we determine to offer different kinds of investment products, we expect to leverage the network of broker-dealers that we have built over time. |
|
Relatively New Market: Investing in life insurance assets in the secondary market is a relatively new and evolving market. Our ability to source and invest in life insurance assets at attractive prices materially depends on the continued growth of the secondary market for life insurance and the continued solvency of the life insurance companies that pay the face value of life insurance policy benefits. |
|
Asset Valuation Assumptions: The valuation of our portfolio life insurance assetsthe principal asset on our balance sheetrequires us to make material assumptions that may ultimately prove to be incorrect. These assumptions include appropriate discount rates, cash flow projections, and the life expectancy estimates we use for these purposes, any of which may ultimately prove to be inaccurate. |
|
Ability to Expand Our Portfolio: Our business model requires us to achieve actual results that are in line with those we expect to attain from our investments in life insurance assets. In this regard, we believe that the larger the portfolio of life insurance assets we own, the greater likelihood there is that we will achieve results matching our expectations. Although we plan to expand the number of investments in life insurance assets using proceeds from the sale of our common stock, we may be unable to meet this goal. Furthermore, even if we successfully grow our portfolio of life insurance assets, we nevertheless may not achieve the results we expect. |
|
Reliance on Financing: We have chosen to finance our business almost entirely through the issuance of debt, including the sale of Renewable Secured Debentures, Series I Secured notes, and our use of a senior secured revolving credit facility. Our business model expects that we will have continued access to financing (including financing to expand or replace our existing financing) in order to purchase a large and diversified portfolio of life insurance assets, and thereafter pay the attendant premiums and financing costs of maintaining that portfolio. We will be required to rely on our access to financing to pay premiums and interest until such time as we experience a significant amount of mortality within our portfolio and begin receiving significant revenues from the receipt of life insurance policy benefits. Even if we obtain the financing we require, we may not receive life insurance policy benefits that match our cash flow projections or meet them in time to earn profits after the payment of financing costs. |
|
Risk of Investment in Life Insurance Assets: Our investments in life insurance assets have inherent risks, including fraud and legal challenges to the validity of the life insurance policies. Examples of fraud include the possibility that the seller of a policy may have provided us with inaccurate or misleading information during the underwriting review process. |
|
Effects of Regulation: Our business is subject to complex state and federal regulation. Changes in state or federal laws and regulations governing our business, or changes in the interpretation of such laws and regulations, could materially and negatively affect our business. |
|
are not required to obtain an attestation and report from our auditors on our managements assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; |
|
are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as compensation discussion and analysis); |
|
are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the say-on-pay, say-on-frequency and say-on-golden-parachute votes); |
|
are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure; |
|
may present only two years of audited financial statements and only two years of related Managements Discussion & Analysis of Financial Condition and Results of Operations, or MD&A; and |
|
are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. |
Common
stock offered by us |
1,600,000 shares |
|||||
Common
stock outstanding prior to this offering |
4,562,000 shares (1) |
|||||
Common
stock to be outstanding after this offering |
8,770,664 shares (1)(2)(3) |
|||||
Use of
proceeds |
Based
on an assumed initial public offering price of $12.50 per share, which is the midpoint of the estimate of the purchase price at which we
expect to offer our shares for sale under this prospectus, we estimate that the net proceeds to us from this offering will be approximately
$18.2 million after payment of underwriting commissions and our estimated offering expenses (approximately $21.0 million if the
underwriters exercise the over-allotment in full). |
|||||
We
intend to use the proceeds from this offering to: |
||||||
promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in
the secondary market for life insurance policies; |
||||||
purchase additional life insurance policies in the secondary market; |
||||||
pay premiums on life insurance policy assets we own; and |
||||||
fund portfolio operations and for working capital purposes. |
||||||
See
Use of Proceeds for more information. |
||||||
Risk
factors |
You
should read the Risk Factors section of this prospectus beginning on page 12 for a discussion of factors to consider carefully before
deciding to invest in shares of our common stock. |
|||||
Proposed NASDAQ Capital Market symbol |
GWGH
(4) |
(1) |
Excludes 1,000,000 shares of our common stock currently reserved for issuance under our 2013 Stock Incentive Plan, of which there are 380,500 common shares subject to outstanding incentive grants. Also excludes 415,954 common shares that are issuable upon the exercise of outstanding warrants. |
(2) |
Includes 2,608,664 shares of our common stock to be issued immediately prior to the closing of this offering upon the conversion, at our election, of 3,478,219 shares of our Series A Convertible Preferred Stock that are currently issued and outstanding. We may elect not to cause the conversion of our Series A Convertible Preferred Stock in connection with this offering. |
(3) |
Excludes an aggregate of 48,000 shares (or 55,200 shares if the underwriters exercise the over-allotment in full) of our common stock issuable upon the exercise of warrants we expect to grant to the underwriters for this offering, and excludes up to an aggregate of 240,000 shares issuable to the underwriters if they exercise the over-allotment option in full, as described under Underwriting. |
(4) |
We have reserved the symbol GWGH for purposes of listing our common stock on The NASDAQ Capital Market and have applied to list our common stock on such exchange. |
|
changes in the secondary market for life insurance; |
|
our limited operating history; |
|
the valuation of assets reflected on our financial statements; |
|
the reliability of assumptions underlying our actuarial models; |
|
the reliability of assumptions underlying our life expectancy estimates; |
|
our reliance on debt financing; |
|
risks relating to the validity and enforceability of the life insurance policies we purchase; |
|
our reliance on information provided and obtained by third parties; |
|
federal and state regulatory matters, including the effect and outcome of current regulatory investigations; |
|
additional expenses, not reflected in our operating history, related to being a public reporting company; |
|
competition in the secondary life insurance market; |
|
the relative illiquidity of life insurance policies; |
|
life insurance company credit exposure; |
|
economic outlook; |
|
performance of our investments in life insurance policies; |
|
financing requirements; |
|
litigation risks; and |
|
restrictive covenants contained in borrowing agreements. |
|
the inability to locate sufficient numbers of life insurance policy sellers and agents to source such sellers; |
|
the inability to convince life insurance policy owners of the benefits of selling their life insurance policy; |
|
competition from other companies in the life insurance secondary market; |
|
negative publicity about the market based on actual or perceived abuses; and |
|
the adoption of additional governmental regulation. |
|
assess the magnitude of impact that hundreds of different types of health impairments have on senior mortality on a case-by-case basis; |
|
apply credits and debits during the underwriting process in a manner that accounts for the different impacts of the same impairments for males and females; and |
|
reflect the difference in mortality between insureds who have sold policies and the group of 90,000 insureds underwritten by 21st Services, most of whom did not ultimately sell their policies in the life settlement market (such difference is frequently referred to in the life-settlement industry as anti-selection). |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
Nine
months ending December 31, 2014 |
$ | 8,323,000 | ||||
2015
|
8,638,000 | |||||
2016
|
7,193,000 | |||||
2017
|
4,252,000 | |||||
2018
|
754,000 | |||||
Thereafter |
64,000 | |||||
$ | 29,224,000 |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
Nine
months ending December 31, 2014 |
$ | 31,109,000 | ||||
2015
|
44,587,000 | |||||
2016
|
34,623,000 | |||||
2017
|
13,094,000 | |||||
2018
|
6,779,000 | |||||
Thereafter |
18,873,000 | |||||
$ | 149,065,000 |
|
are not required to obtain an attestation and report from our auditors on our managements assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; |
|
are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as compensation discussion and analysis); |
|
are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the say-on-pay, say-on-frequency and say-on-golden-parachute votes); |
|
are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure; |
|
may present only two years of audited financial statements and only two years of related Managements Discussion & Analysis of Financial Condition and Results of Operations, or MD&A; and |
|
are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. |
|
variations in our operating results; |
|
the level and quality of securities analysts coverage for our common stock; |
|
announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; |
|
announcements by third parties of significant claims or proceedings against us; and |
|
future sales of our common stock. |
|
promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in the secondary market for life insurance policies; |
|
purchase additional life insurance policies in the secondary market; |
|
pay premiums on life insurance policy assets we own; and |
|
fund our portfolio operations and for working capital purposes. |
Year |
Premiums |
|||||
---|---|---|---|---|---|---|
Nine
months ending December 31, 2014 |
$ | 17,882,000 | ||||
2015
|
26,078,000 | |||||
2016
|
28,550,000 | |||||
2017
|
32,109,000 | |||||
2018
|
35,155,000 | |||||
$ | 139,774,000 |
At March 31, 2014 |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Actual |
As Adjusted |
||||||||||
Debt: |
(Dollars in thousands, except per-share amounts) (Unaudited) |
||||||||||
Renewable
Secured Debentures |
$ | 145,989 | $ | 145,989 | |||||||
Series I
Secured notes (1) |
28,602 | 28,602 | |||||||||
Revolving
credit facility (2) |
79,000 | 79,000 | |||||||||
Total debt
|
$ | 253,591 | $ | 253,591 | |||||||
Preferred
stock: |
|||||||||||
Series A
Convertible Preferred (par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,478,219; liquidation preference of $26,087,000
on March 31, 2014) (3) |
$ | 25,036 | $25,036 | ||||||||
Stockholders equity (accumulated deficit): |
|||||||||||
Common stock
(par value $0.001 per share; shares authorized 210,000,000; shares issued and outstanding 4,562,000) |
$5 | $9 | |||||||||
Additional
paid-in capital |
2,872 | 21,068 | |||||||||
Retained
earnings (accumulated deficit) |
(10,340 | ) | (10,340 | ) | |||||||
Total
stockholders equity (accumulated deficit) |
$ | (7,463 | ) | $10,737 | |||||||
Total debt,
preferred stock and common stockholders equity |
$ | 271,164 | $289,364 |
(1) |
The total outstanding face amount of Series I Secured notes outstanding at March 31, 2014 was $29,224,000, less unamortized selling costs of $622,000. The weighted-average interest rate of our outstanding Series I Secured notes at March 31, 2014 was approximately 8.35%, and the weighted-average maturity was approximately 2.24 years. |
(2) |
The interest rate of our revolving credit line floats in conjunction with advances made thereunder. The weighted-average interest rate payable under our revolving credit line at March 31, 2014 was approximately 6.21%. Amounts owing under our revolving credit line come due on December 31, 2016. |
(3) |
As of March 31, 2014, we had issued 3,395,000 preferred shares resulting in gross consideration of $25,261,000 (including cash proceeds, conversion of Series I Secured notes and accrued interest on Series I notes, and conversion of preferred dividends payable) net of redemptions. We incurred Series A preferred stock issuance costs of $2,838,000, of which $2,510,000 was amortized to additional paid in capital as of March 31, 2014, resulting in a carrying amount of $25,036,000. |
Assumed public offering price |
$12.50 | |||||
Pro
forma net tangible book value before offering |
$2.28 | |||||
Increase in pro forma net tangible book value attributable to new investors |
$1.10 | |||||
Pro
forma as adjusted net tangible book value after offering (1) |
$3.38 | |||||
Dilution in pro forma net tangible book value to new investors |
$9.12 |
(1) |
Net tangible book value is adjusted to reflect the conversion, at our election, of all 3,478,219 shares of our Series A Convertible Preferred Stock issued and outstanding at March 31, 2014 into an aggregate of 2,608,664 shares of our common stock at the effective time of this offering (which election we may ultimately determine not to make). |
Share Purchased |
Total Consideration |
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number |
Percent |
Amount |
Percent |
Average Price Per Share |
||||||||||||||||||
Existing
Stockholders |
7,170,664 | 81.8 | % | $ | 30,160,356 | 60.1 | % | $ | 4.21 | |||||||||||||
New
investors |
1,600,000 | 18.2 | % | $ | 20,000,000 | 39.9 | % | $ | 12.50 | |||||||||||||
Total
|
8,770,664 | 100.0 | % | $ | 50,160,356 | 100.0 | % | $ | 5.72 |
March 31, 2014 |
December 31, 2013 |
December 31, 2012 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total
Assets |
$ | 287,577,263 | $ | 275,380,476 | $ | 197,948,035 | ||||||||
Investment in Portfolio |
254,503,535 | 234,672,794 | 164,317,183 | |||||||||||
Cash
and Cash Equivalents |
28,083,299 | 33,449,793 | 27,497,044 | |||||||||||
Restricted Cash |
2,853,763 | 5,832,970 | 2,093,092 | |||||||||||
Total
Liabilities |
270,004,316 | 256,149,798 | 175,303,946 | |||||||||||
Revolving Credit Facility |
79,000,000 | 79,000,000 | 71,000,000 | |||||||||||
Series
I Secured notes (1) |
28,602,238 | 29,275,202 | 37,844,711 | |||||||||||
Renewable Secured Debentures (2) |
145,989,431 | 131,646,062 | 55,718,950 | |||||||||||
Stockholder Preferred and Common Equity |
17,572,947 | 19,530,678 | 22,644,089 |
(1) |
The total outstanding face amount of Series I Secured notes outstanding at March 31, 2014 was $29,224,000, less unamortized selling costs of $622,000. |
(2) |
The total outstanding face amount of Renewable Secured Debentures outstanding at March 31, 2014 was $149,065,000 plus $2,343,000 of subscriptions in process, less unamortized selling costs of $5,418,000. |
March 31, 2014 |
December 31, 2013 |
December 31, 2012 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total
Revenue |
$ | 5,523,572 | $ | 33,064,774 | $ | 17,525,798 | ||||||||
Gain
on Life Insurance Contracts |
5,516,205 | 29,513,642 | 17,436,743 | |||||||||||
Interest Expense |
6,326,548 | 20,762,644 | 10,878,627 | |||||||||||
Net
Income (Loss) |
(1,901,170 | ) | (194,955 | ) | (1,012,899 | ) |
March 31, 2014 |
December 31, 2013 |
|||||
---|---|---|---|---|---|---|
11.69% |
11.69% |
|
Policy Benefits Realized. We recognize the difference between the death benefits and carrying values of the policy when an insured event has occurred and we determine that settlement and ultimate collection of the death benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. We generally collect the face value of the life insurance policy from the insurance company within 45 days of the insureds mortality. |
|
Change in Fair Value of Life Insurance Policies. We have elected to carry our investments in life insurance policies at fair value in accordance with ASC 325-30, Investments in Life Insurance Contracts . Accordingly, we value our investments in our portfolio of life insurance policies each reporting period in accordance with the fair value principles discussed herein, which includes the expected payment of premiums for future periods. |
|
Sale of a Life Insurance Policy or a Portfolio of Life Insurance Policies. In an event of a sale of a policy, we recognize gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale. |
|
Selling, General and Administrative Expenses. We recognize and record expenses incurred in the operations of the purchasing and servicing of life insurance policies. These expenses include professional fees, salaries, and sales and marketing expenditures. |
|
Interest Expense. We recognize and record interest expenses associated with the costs of financing our life insurance portfolio for the current period. These expenses include interest paid to our senior lender under our revolving credit facility, as well as all interest paid on our debentures and other outstanding indebtedness such as our subsidiary secured notes and dividends on convertible, redeemable preferred stock. When we issue long-term indebtedness, we amortize the issuance costs associated with such indebtedness over the outstanding term of the financing, and classify it as interest expense. |
Three months ended: |
March 31, 2014 |
March 31, 2013 |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statutory
federal income tax |
$ | (971,000 | ) | 34.0 | % | $ | 215,000 | 34.0 | % | ||||||||||
State income
taxes, net of federal benefit |
(143,000 | ) | 5.0 | % | 85,000 | 13.5 | % | ||||||||||||
Series A
preferred stock dividends |
216,000 | (7.6 | )% | 216,000 | 34.1 | % | |||||||||||||
Other
permanent differences |
(57,000 | ) | 2.0 | % | 50,000 | 7.8 | % | ||||||||||||
Total income
tax expense |
$ | (955,000 | ) | 33.4 | % | $ | 566,000 | 89.4 | % |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
Nine months
ending December 31, 2014 |
$ | 8,323,000 | ||||
2015
|
8,638,000 | |||||
2016
|
7,193,000 | |||||
2017
|
4,252,000 | |||||
2018
|
754,000 | |||||
Thereafter
|
64,000 | |||||
$ | 29,224,000 |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
Nine months
ending December 31, 2014 |
$ | 31,109,000 | ||||
2015
|
44,587,000 | |||||
2016
|
34,623,000 | |||||
2017
|
13,094,000 | |||||
2018
|
6,779,000 | |||||
Thereafter
|
18,873,000 | |||||
$ | 149,065,000 |
Issuer/Borrower |
Principal Amount Outstanding |
Weighted Average Interest Rate |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
GWG Holdings,
Inc. Renewable Secured Debentures |
$ | 149,065,000 | 7.53 | % | ||||||
GWG Life
Settlements, LLC Series I Secured notes |
29,224,000 | 8.35 | % | |||||||
GWG DLP
Funding II, LLC Revolving credit facility |
79,000,000 | 6.21 | % | |||||||
Total
|
$ | 257,289,000 | 7.21 | % |
Portfolio Discount Rate |
11% |
12% |
13% |
14% |
15% |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Value of
portfolio |
$ | 263,696,606 | $ | 250,538,024 | $ | 238,394,725 | $ | 227,165,747 | $ | 216,762,110 | ||||||||||||
Cash and cash
equivalents |
30,937,062 | 30,937,062 | 30,937,062 | 30,937,062 | 30,937,062 | |||||||||||||||||
Total assets
|
294,633,668 | 281,475,086 | 269,331,787 | 258,102,808 | 247,699,172 | |||||||||||||||||
Revolving
credit facility Autobahn/DZ Bank |
79,000,000 | 79,000,000 | 79,000,000 | 79,000,000 | 79,000,000 | |||||||||||||||||
Net after
revolving credit facility |
215,633,668 | 202,475,086 | 190,331,787 | 179,102,808 | 168,699,172 | |||||||||||||||||
Series I
Secured notes and Renewable Secured Debentures |
178,289,219 | 178,289,219 | 178,289,219 | 178,289,219 | 178,289,219 | |||||||||||||||||
Net after
Series I Secured notes and Renewable Secured Debentures |
37,344,449 | 24,185,867 | 12,042,568 | 813,590 | (9,590,047 | ) | ||||||||||||||||
Impairment to
Series I Secured notes and Renewable Secured Debentures |
No impairment |
No impairment |
No impairment |
No impairment |
Impairment |
Quarter End Date |
Portfolio Face Amount |
12-Month Trailing Benefits Collected |
12-Month Trailing Premiums Paid |
12-Month Trailing Benefits/Premium Coverage Ratio |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2012 |
$ | 482,455,000 | $ | 4,203,000 | $ | 14,977,000 | 28.06 | % | ||||||||||
June 30, 2012
|
489,255,000 | 8,703,000 | 15,412,000 | 56.47 | % | |||||||||||||
September 30,
2012 |
515,661,000 | 7,833,000 | 15,837,000 | 49.46 | % | |||||||||||||
December 31,
2012 |
572,245,000 | 7,350,000 | 16,597,000 | 44.28 | % | |||||||||||||
March 31,
2013 |
639,755,000 | 11,350,000 | 18,044,000 | 62.90 | % | |||||||||||||
June 30, 2013
|
650,655,000 | 13,450,000 | 19,182,000 | 70.11 | % | |||||||||||||
September 30,
2013 |
705,069,000 | 18,450,000 | 20,279,000 | 90.98 | % | |||||||||||||
December 31,
2013 |
740,648,000 | 16,600,000 | 21,733,000 | 76.38 | % | |||||||||||||
March 31,
2014 |
771,940,000 | 12,600,000 | 21,930,000 | 57.46 | % |
Year |
Premiums and Servicing |
|||||
---|---|---|---|---|---|---|
Nine months
ending December 31, 2014 |
$ | 18,025,000 | ||||
2015
|
26,221,000 | |||||
2016
|
28,693,000 | |||||
2017
|
32,252,000 | |||||
2018
|
35,298,000 | |||||
Total
|
$ | 140,489,000 |
Nine months
ending December 31, 2014 |
$ | 78,000 | ||||
2015
|
$ | 70,000 | ||||
Total
|
$ | 148,000 |
Three months ended March 31, |
2014 |
2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
GAAP net gain
(loss) |
$ | (1,901,000 | ) | $ | 67,000 | |||||
Unrealized
fair value gain (1) |
(11,359,000 | ) | (11,495,000 | ) | ||||||
Adjusted cost
basis increase (2) |
11,397,000 | 10,256,000 | ||||||||
Accrual of
unrealized actuarial gain (3) |
7,305,000 | 5,033,000 | ||||||||
Total
adjusted non-GAAP income (4) |
$ | 5,442,000 | $ | 3,861,000 |
(1) |
Reversal of unrealized fair value gain of life insurance policies for current period. |
(2) |
Adjusted cost basis is increased to include those acquisition and servicing expenses that are not capitalized by GAAP. |
(3) |
Accrual of actuarial gain at expected internal rate of return based on investment cost basis for the period. |
(4) |
We must maintain an annual positive consolidated net income, calculated on a non-GAAP basis, to maintain compliance with our revolving credit facility with DZ Bank/Autobahn. |
As of March 31, 2014 |
As of December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
GAAP net
worth (1) |
$ | 17,573,000 | $ | 19,231,000 | ||||||
Less
intangible assets (2) |
(7,179,000 | ) | (6,068,000 | ) | ||||||
GAAP tangible
net worth |
10,394,000 | 13,163,000 | ||||||||
Unrealized
fair value gain (3) |
(126,103,000 | ) | (114,744,000 | ) | ||||||
Adjusted cost
basis increase (4) |
117,602,000 | 106,201,000 | ||||||||
Accrual of
unrealized actuarial gain (5) |
56,972,000 | 49,666,000 | ||||||||
Total
adjusted non-GAAP tangible net worth (6) |
$ | 58,865,000 | $ | 54,286,000 |
(1) |
Includes termination of redeemable members interest prior to corporate conversion and preferred stock classified as temporary equity. |
(2) |
Unamortized portion of deferred financing costs and pre-paid insurance. |
(3) |
Reversal of cumulative unrealized fair value gain or loss of life insurance policies. |
(4) |
Adjusted cost basis is increased by acquisition and servicing expenses which are not capitalized under GAAP. |
(5) |
Accrual of cumulative actuarial gain at expected internal rate of return based on investment cost basis. |
(6) |
We must maintain a total adjusted non-GAAP tangible net worth of $15 million to maintain compliance with our revolving credit facility with DZ Bank/Autobahn. |
As of March 31, 2014 |
As of December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Weighted-average expected IRR (1) |
12.17 | % | 12.21 | % | ||||||
Weighted-average revolving credit facility interest rate (2) |
6.21 | % | 6.19 | % | ||||||
Excess spread
(3) |
5.96 | % | 6.02 | % | ||||||
Total
weighted-average interest rate on indebtedness for borrowed money (4) |
7.21 | % | 7.20 | % | ||||||
Total excess
spread |
4.96 | % | 5.01 | % |
(1) |
This represents the weighted-average expected internal rate of return of the life insurance policies as of the measurement date based upon our investment cost basis in the insurance policies and expected cash flows from the life insurance portfolio. Our investment cost basis is calculated as our cash investment in the life insurance policies, without regard to GAAP-based fair value measurements, and is set forth below: |
Investment Cost Basis |
As of March 31, 2014 |
As of December 31, 2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
GAAP fair
value |
$ | 254,504,000 | $ | 234,673,000 | ||||||
Unrealized
fair value gain (A) |
(126,103,000 | ) | (114,744,000 | ) | ||||||
Adjusted cost
basis increase (B) |
117,602,000 | 106,201,000 | ||||||||
Investment
cost basis (C) |
$ | 246,003,000 | $ | 226,130,000 |
(A) |
This represents the reversal of cumulative unrealized GAAP fair value gain of life insurance policies. |
(B) |
Adjusted cost basis is increased to include those acquisition and servicing expenses that are not capitalized by GAAP. |
(C) |
This is the full cash investment cost basis in life insurance policies from which our expected internal rate of return is calculated. |
(2) |
This is the weighted-average revolving credit facility interest rate as of the measurement date. |
(3) |
We must maintain an excess spread of 2.00% relating to our revolving credit facility to maintain compliance under such facility. |
(4) |
Represents the weighted-average interest rate paid on all outstanding indebtedness as of the measurement date, determined as follows: |
Outstanding Indebtedness |
As of March 31, 2014 |
As of December 31, 2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Revolving
credit facility |
$ | 79,000,000 | $ | 79,000,000 | ||||||
Series I
Secured notes |
29,224,000 | 29,744,000 | ||||||||
Renewable
Secured Debentures |
149,065,000 | 134,891,000 | ||||||||
Total
|
$ | 257,289,000 | $ | 243,635,000 | ||||||
Interest
Rates on Indebtedness |
||||||||||
Revolving
credit facility |
6.21 | % | 6.19 | % | ||||||
Series I
Secured notes |
8.35 | % | 8.35 | % | ||||||
Renewable
Secured Debentures |
7.53 | % | 7.53 | % | ||||||
Weighted-average interest rates on indebtedness |
7.21 | % | 7.20 | % |
As of March 31, 2014 |
As of December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Life
insurance portfolio policy benefits |
$ | 771,940,000 | $ | 740,648,000 | ||||||
Discount rate
of future cash flows |
7.21 | % | 7.20 | % | ||||||
Net present
value of Life insurance portfolio policy benefits |
$ | 325,006,000 | $ | 302,761,000 | ||||||
Cash and cash
equivalents |
30,937,000 | 39,283,000 | ||||||||
Total
Coverage |
355,943,000 | 332,044,000 | ||||||||
Revolving
credit facility |
79,000,000 | 79,000,000 | ||||||||
Series I
Secured notes |
29,224,000 | 29,744,000 | ||||||||
Renewable
Secured Debentures |
149,065,000 | 134,891,000 | ||||||||
Total
Indebtedness |
$ | 257,289,000 | $ | 243,635,000 | ||||||
Debt Coverage
Ratio |
72.28 | % | 71.23 | % | ||||||
Subordination
Ratio |
22.19 | % | 23.10 | % |
|
purchasing life insurance policy assets which generate expected internal rates of returns in excess of our cost of capital; |
|
paying the life insurance assets premiums and costs until the insureds mortality; |
|
obtaining a large and diverse portfolio of insurance policy assets to mitigate actuarial risk; |
|
maintaining diversified funding sources to reduce our overall cost of financing; |
|
maintaining rigorous portfolio monitoring and servicing practices; and |
|
if appropriate, engaging in hedging strategies that reduce potential volatility to our cost of financing. |
|
Industry Experience: We have actively participated in the development of the secondary market of life insurance as a principal purchaser and financier within the asset class since 2006. Our position within the marketplace has allowed us to gain a deep understanding of the life insurance secondary market. We have participated in the leadership of various industry associations and forums, including the Life Insurance Settlement Association (LISA) and the Insurance Studies Institute (ISI). Our experience gives us confidence in building a company to compete in the industry and acquire a portfolio of life insurance policies that will perform to our expectations. |
|
Operational Platform: We have built and continue to refine and develop an operational platform and systems for efficiently tracking, processing, and servicing life insurance policies that we believe provide competitive advantages when participating in the life insurance secondary marketplace. |
|
Origination and Underwriting Practices: We seek to use underwriting review processes and file documentation standards that generally meet published guidelines for rated securitizations of life insurance portfolios. We purchase life insurance policies we consider to be non-contestable and that meet our underwriting criteria and reviews. We consider a life insurance policy to be non-contestable once applicable state law prohibits the insurer from challenging the validity of the policy due to fraud. In this regard, state non-contestability laws generally require a period of one to two years to elapse after the initial issuance of the policy before that policy is considered non-contestable under state law. Non-contestability laws do not, however, prevent an insurer from challenging the validity of a policy procured by fraud for lack of an insurable interest at the time at which the policy was purchased, such as is the case with so-called stranger-originated life insurance policies. To the extent we use modified methodologies for estimating life expectancies for small face policies, those modified methodologies may not meet published guidelines for rated securitizations of life insurance portfolios. |
|
Origination Relationships and Strategies: We have established origination relationships with life insurance policy brokers and insurance agents who submit policies for our purchase or financing. Our referral base knows our underwriting standards for purchasing life insurance policies in the secondary market, which provides confidence in our bidding and closing processes and streamlines our own due-diligence process. We expect to expand our origination methodology and channels with the proceeds of this offering (e.g., the addition of consumer marketing). |
|
Life Expectancy Methodology: We generally rely on two life expectancy estimates obtained from independent third-party medical-actuarial underwriting firms to arrive at a life expectancy estimate we use for valuing a life insurance asset. For a majority of our life insurance asset purchases, we rely on estimates obtained from 21st Services and AVS Underwriting to develop our life expectancy estimate. We may, however, also obtain and use life expectancy estimates from other medical-actuarial underwriting firms. As explained above, we may from time to time modify our underwriting review processes, including our methodology for arriving at life expectancy estimates we use in ascribing value to a life insurance asset. |
|
Pricing Software and Methodology: To calculate our expected returns on the investments we make in life insurance assets, we use actuarial pricing methodologies and software tools built by a leading independent actuarial service firm and currently supported by Modeling Actuarial Pricing Systems, Inc. (MAPS). |
|
Financing Strategy: We have actively developed diversified financing strategy for accessing capital markets in support of our buy-and-hold strategy for our portfolio of life insurance policies, ranging from institutional bank financing to a network of broker-dealers registered with the Financial Industry Regulatory Authority (FINRA), many of whom have participated in one or more of our Series I Secured note financing, our Series A preferred stock financing, or our Renewable Secured Debenture financing. If in the future we determine to offer different kinds of investment products, we expect to leverage the network of broker-dealers that we have built over time. |
|
Relatively New Market: Investing in life insurance assets in the secondary market is a relatively new and evolving market. Our ability to source and invest in life insurance assets at attractive prices materially depends on the continued growth of the secondary market for life insurance and the continued solvency of the life insurance companies that pay the face value of life insurance policy benefits. |
|
Asset Valuation Assumptions: The valuation of our portfolio life insurance assetsthe principal asset on our balance sheetrequires us to make material assumptions that may ultimately prove to be incorrect. These assumptions include appropriate discount rates, cash flow projections, and the life expectancy estimates we use for these purposes, any of which may ultimately prove to be inaccurate. |
|
Ability to Expand Our Portfolio: Our business model requires us to achieve actual results that are in line with those we expect to attain from our investments in life insurance assets. In this regard, we believe that the larger the portfolio of life insurance assets we own, the greater likelihood there is that we will achieve results matching our expectations. Although we plan to expand the number of investments in life insurance assets using proceeds from the sale of our common stock, we may be unable to meet this goal. Furthermore, even if we successfully grow our portfolio of life insurance assets, we nevertheless may not achieve the results we expect. |
|
Reliance on Financing: We have chosen to finance our business almost entirely through the issuance of debt, including the sale of Renewable Secured Debentures, Series I Secured notes, and our use of a senior secured revolving credit facility. Our business model expects that we will have continued access to financing (including financing to expand or replace our existing financing) in order to purchase a large and diversified portfolio of life insurance assets, and thereafter pay the attendant premiums and financing costs of maintaining that portfolio. We will be required to rely on our access to financing to pay premiums and interest until such time as we experience a significant amount of mortality within our portfolio and begin receiving significant revenues from the receipt of life insurance policy benefits. Even if we obtain the financing we require, we may not receive life insurance policy benefits that match our cash flow projections or meet them in time to earn profits after the payment of financing costs. |
|
Risk of Investment in Life Insurance Assets: Our investments in life insurance assets have inherent risks, including fraud and legal challenges to the validity of the life insurance policies. Examples of fraud include the possibility that the seller of a policy may have provided us with inaccurate or misleading information during the underwriting review process. |
|
Effects of Regulation: Our business is subject to complex state and federal regulation. Changes in state or federal laws and regulations governing our business, or changes in the interpretation of such laws and regulations, could materially and negatively affect our business. |
Total
portfolio face value of policy benefits |
$ | 771,940,000 | ||||
Average
face value per policy |
$ | 2,699,000 | ||||
Average
face value per insured life |
$ | 3,015,000 | ||||
Average
age of insured (yrs.)* |
82.3 | |||||
Average
life expectancy estimate (yrs.)* |
7.02 | |||||
Total
number of policies |
286 | |||||
Number of
unique lives |
256 | |||||
Demographics |
67% Males; 33% Females |
|||||
Number of
smokers |
3 insureds are smokers |
|||||
Largest
policy as % of total portfolio |
1.30 | % | ||||
Average
policy as % of total portfolio |
0.35 | % | ||||
Average
Annual Premium as % of face value |
3.15 | % |
* |
Averages presented in the table are weighted averages. |
Min Age |
Max Age |
Policy Benefits |
Weighted Average Life Expectancy (yrs.) |
Distribution |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
65 |
69 | $ | 11,156,000 | 8.27 | 1.45 | % | ||||||||||||
70 |
74 | 43,617,000 | 9.16 | 5.65 | % | |||||||||||||
75 |
79 | 178,198,000 | 8.57 | 23.08 | % | |||||||||||||
80 |
84 | 293,719,000 | 7.44 | 38.05 | % | |||||||||||||
85 |
89 | 219,929,000 | 5.08 | 28.49 | % | |||||||||||||
90 |
95 | 25,321,000 | 3.95 | 3.28 | % | |||||||||||||
Total |
$ | 771,940,000 | 7.02 | 100.00 | % |
Min Age |
Max Age |
Policies |
Weighted Average Life Expectancy (yrs.) |
Distribution |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
65 |
69 | 8 | 8.27 | 2.80 | % | |||||||||||||
70 |
74 | 19 | 9.16 | 6.64 | % | |||||||||||||
75 |
79 | 59 | 8.57 | 20.63 | % | |||||||||||||
80 |
84 | 104 | 7.44 | 36.36 | % | |||||||||||||
85 |
89 | 84 | 5.08 | 29.37 | % | |||||||||||||
90 |
95 | 12 | 3.95 | 4.20 | % | |||||||||||||
Total |
286 | 7.02 | 100.00 | % |
Min LE (Months) |
Max LE (Months) |
Policy Benefits |
Distribution |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
144 |
169 | $ | 5,000,000 | 0.65 | % | |||||||||
120 |
143 | 106,656,000 | 13.82 | % | ||||||||||
96 |
119 | 163,139,000 | 21.13 | % | ||||||||||
72 |
95 | 203,321,000 | 26.34 | % | ||||||||||
48 |
71 | 195,658,000 | 25.34 | % | ||||||||||
16 |
47 | 98,166,000 | 12.72 | % | ||||||||||
Total |
$ | 771,940,000 | 100.00 | % |
Primary Disease Category |
Policy Benefits |
Distribution |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Cancer
|
$ | 49,967,000 | 6.47 | % | ||||||
Cardiovascular
|
154,068,000 | 19.96 | % | |||||||
Cerebrovascular
|
36,985,000 | 4.79 | % | |||||||
Dementia
|
53,949,000 | 6.99 | % | |||||||
Diabetes
|
39,067,000 | 5.06 | % | |||||||
Multiple
|
195,051,000 | 25.27 | % | |||||||
Neurological
Disorders |
13,000,000 | 1.68 | % | |||||||
No Disease
|
69,986,000 | 9.07 | % | |||||||
Other
|
108,167,000 | 14.01 | % | |||||||
Respiratory
Diseases |
51,700,000 | 6.70 | % | |||||||
Total Policy
Benefits |
$ | 771,940,000 | 100.00 | % |
Face Amount |
Gender |
Age (ALB)(1) |
LE(2) |
Carrier |
S&P |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | $ | 4,000,000 | M | 93 | 38.9 | MetLife Investors USA Insurance Company |
AA- |
||||||||||||||||||||
2 | $ | 1,100,000 | M | 93 | 33.1 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
3 | $ | 1,770,726 | F | 93 | 37.2 | Aviva Life Insurance Company |
N/A |
||||||||||||||||||||
4 | $ | 1,000,000 | F | 92 | 43.5 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
5 | $ | 3,200,000 | M | 92 | 66.7 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
6 | $ | 250,000 | M | 91 | 26.1 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
7 | $ | 2,500,000 | M | 90 | 29.7 | Columbus Life Insurance Company |
AA |
||||||||||||||||||||
8 | $ | 3,000,000 | M | 90 | 59.3 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
9 | $ | 500,000 | M | 90 | 25.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
10 | $ | 5,000,000 | F | 90 | 63.7 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
11 | $ | 2,000,000 | F | 90 | 24.6 | Pruco Life Insurance Company |
AA- |
||||||||||||||||||||
12 | $ | 1,000,000 | F | 90 | 41.1 | Protective Life Insurance Company |
AA- |
||||||||||||||||||||
13 | $ | 1,682,773 | F | 89 | 62.1 | Hartford Life and Annuity Insurance Company |
BBB+ |
||||||||||||||||||||
14 | $ | 5,000,000 | M | 89 | 42.1 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
15 | $ | 1,000,000 | M | 89 | 37.8 | State Farm Life Insurance Company |
AA- |
||||||||||||||||||||
16 | $ | 5,000,000 | F | 89 | 43.9 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
17 | $ | 1,000,000 | M | 89 | 16.3 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
18 | $ | 1,000,000 | F | 88 | 62.1 | United of Omaha Life Insurance Company |
A+ |
||||||||||||||||||||
19 | $ | 3,500,000 | F | 88 | 67.7 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
20 | $ | 3,100,000 | F | 88 | 44.8 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
21 | $ | 1,500,000 | F | 88 | 75.9 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
22 | $ | 1,750,000 | M | 88 | 32.0 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
23 | $ | 2,500,000 | F | 88 | 18.3 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
24 | $ | 2,500,000 | F | 88 | 18.3 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
25 | $ | 3,000,000 | F | 88 | 44.3 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
26 | $ | 500,000 | F | 88 | 36.8 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
27 | $ | 1,000,000 | F | 88 | 36.8 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
28 | $ | 1,000,000 | F | 88 | 36.8 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
29 | $ | 500,000 | F | 88 | 36.8 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
30 | $ | 5,000,000 | F | 88 | 51.2 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
31 | $ | 5,000,000 | F | 88 | 28.4 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
32 | $ | 715,000 | F | 88 | 71.7 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
33 | $ | 1,203,520 | M | 88 | 54.7 | Columbus Life Insurance Company |
AA |
||||||||||||||||||||
34 | $ | 1,350,000 | F | 88 | 46.7 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
35 | $ | 2,000,000 | F | 88 | 40.2 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
36 | $ | 600,000 | F | 88 | 31.9 | Columbus Life Insurance Company |
AA |
||||||||||||||||||||
37 | $ | 5,000,000 | F | 87 | 57.4 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
38 | $ | 2,500,000 | F | 87 | 59.3 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
39 | $ | 2,500,000 | M | 87 | 50.1 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
40 | $ | 5,000,000 | M | 87 | 64.8 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
41 | $ | 1,500,000 | M | 87 | 50.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
42 | $ | 1,500,000 | M | 87 | 50.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
43 | $ | 1,000,000 | F | 87 | 77.9 | Transamerica Life Insurance Company |
AA- |
Face Amount |
Gender |
Age (ALB)(1) |
LE(2) |
Carrier |
S&P |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
44 | $ | 250,000 | F | 87 | 77.9 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
45 | $ | 500,000 | M | 87 | 73.1 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
46 | $ | 4,785,380 | F | 87 | 52.1 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
47 | $ | 8,985,000 | M | 87 | 42.5 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
48 | $ | 1,803,455 | F | 87 | 60.7 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
49 | $ | 1,529,270 | F | 87 | 60.7 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
50 | $ | 5,000,000 | M | 87 | 63.5 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
51 | $ | 2,225,000 | F | 87 | 84.9 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
52 | $ | 3,000,000 | F | 87 | 94.0 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
53 | $ | 1,500,000 | M | 87 | 57.2 | Union Central Life Insurance Company |
A+ |
||||||||||||||||||||
54 | $ | 100,000 | M | 87 | 34.2 | Protective Life Insurance Company |
AA- |
||||||||||||||||||||
55 | $ | 100,000 | M | 87 | 34.2 | Protective Life Insurance Company |
AA- |
||||||||||||||||||||
56 | $ | 100,000 | M | 87 | 34.2 | Protective Life Insurance Company |
AA- |
||||||||||||||||||||
57 | $ | 3,500,000 | F | 87 | 52.7 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
58 | $ | 3,000,000 | M | 87 | 44.1 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
59 | $ | 500,000 | F | 86 | 80.5 | Sun Life Assurance Company of Canada (U.S.) |
BBB |
||||||||||||||||||||
60 | $ | 5,000,000 | F | 86 | 45.9 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
61 | $ | 3,000,000 | M | 86 | 64.7 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
62 | $ | 250,000 | M | 86 | 84.0 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
63 | $ | 6,000,000 | F | 86 | 68.0 | Sun Life Assurance Company of Canada (U.S.) |
BBB |
||||||||||||||||||||
64 | $ | 4,000,000 | F | 86 | 84.5 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
65 | $ | 5,570,000 | F | 86 | 59.2 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
66 | $ | 5,570,000 | F | 86 | 59.2 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
67 | $ | 1,000,000 | F | 86 | 46.7 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
68 | $ | 5,000,000 | F | 86 | 42.2 | Penn Mutual Life Insurance Company |
A+ |
||||||||||||||||||||
69 | $ | 1,000,000 | M | 86 | 66.3 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
70 | $ | 10,000,000 | F | 86 | 84.3 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
71 | $ | 2,500,000 | M | 86 | 59.2 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
72 | $ | 1,000,000 | F | 86 | 63.0 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
73 | $ | 2,000,000 | F | 86 | 63.0 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
74 | $ | 800,000 | M | 86 | 67.0 | National Western Life Insurance Company |
A |
||||||||||||||||||||
75 | $ | 200,000 | M | 86 | 59.7 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
76 | $ | 4,445,467 | M | 86 | 70.1 | Penn Mutual Life Insurance Company |
A+ |
||||||||||||||||||||
77 | $ | 7,500,000 | M | 86 | 62.0 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
78 | $ | 3,600,000 | F | 86 | 69.7 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
79 | $ | 1,000,000 | F | 86 | 38.2 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
80 | $ | 4,513,823 | F | 86 | 33.8 | Aviva Life Insurance Company |
N/A |
||||||||||||||||||||
81 | $ | 2,000,000 | M | 86 | 50.5 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
82 | $ | 2,000,000 | F | 86 | 86.9 | U.S. Financial Life Insurance Company |
A+ |
||||||||||||||||||||
83 | $ | 1,000,000 | M | 85 | 72.4 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
84 | $ | 2,000,000 | M | 85 | 72.4 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
85 | $ | 5,000,000 | M | 85 | 60.1 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
86 | $ | 1,200,000 | M | 85 | 71.6 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
87 | $ | 1,000,000 | F | 85 | 96.8 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
88 | $ | 3,000,000 | M | 85 | 96.5 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
89 | $ | 8,500,000 | M | 85 | 93.1 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
90 | $ | 1,000,000 | M | 85 | 35.5 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
91 | $ | 500,000 | M | 85 | 94.0 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
92 | $ | 500,000 | F | 85 | 67.5 | Beneficial Life Insurance Company |
N/A |
||||||||||||||||||||
93 | $ | 5,000,000 | M | 85 | 93.3 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
94 | $ | 2,000,000 | M | 85 | 111.5 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
95 | $ | 2,000,000 | M | 85 | 111.5 | ING Life Insurance and Annuity Company |
A- |
Face Amount |
Gender |
Age (ALB)(1) |
LE(2) |
Carrier |
S&P |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
96 | $ | 2,000,000 | M | 85 | 111.5 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
97 | $ | 1,365,000 | F | 84 | 97.3 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
98 | $ | 1,000,000 | M | 84 | 50.9 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
99 | $ | 3,750,000 | M | 84 | 87.4 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
100 | $ | 2,000,000 | M | 84 | 96.7 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
101 | $ | 1,000,000 | M | 84 | 71.6 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
102 | $ | 2,000,000 | F | 84 | 97.4 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
103 | $ | 3,000,000 | F | 84 | 96.1 | Sun Life Assurance Company of Canada (U.S.) |
BBB |
||||||||||||||||||||
104 | $ | 2,328,547 | M | 84 | 55.5 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
105 | $ | 2,000,000 | M | 84 | 55.5 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
106 | $ | 2,000,000 | M | 84 | 73.4 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
107 | $ | 1,500,000 | M | 84 | 60.4 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
108 | $ | 1,500,000 | M | 84 | 60.4 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
109 | $ | 3,000,000 | F | 84 | 83.3 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
110 | $ | 5,000,000 | M | 84 | 85.1 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
111 | $ | 1,000,000 | M | 84 | 58.6 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
112 | $ | 1,800,000 | M | 84 | 62.6 | John Hancock Variable Life Insurance Company |
AA- |
||||||||||||||||||||
113 | $ | 5,000,000 | F | 84 | 105.1 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
114 | $ | 2,000,000 | M | 84 | 73.3 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
115 | $ | 1,750,000 | M | 84 | 73.3 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
116 | $ | 2,000,000 | M | 84 | 45.5 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
117 | $ | 1,425,000 | M | 84 | 95.1 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
118 | $ | 5,000,000 | F | 83 | 109.4 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
119 | $ | 1,000,000 | F | 83 | 96.0 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
120 | $ | 6,000,000 | F | 83 | 123.3 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
121 | $ | 1,500,000 | M | 83 | 60.4 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
122 | $ | 1,500,000 | F | 83 | 121.6 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
123 | $ | 4,000,000 | M | 83 | 47.5 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
124 | $ | 1,000,000 | M | 83 | 94.0 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
125 | $ | 2,000,000 | F | 83 | 111.2 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
126 | $ | 1,000,000 | M | 83 | 65.6 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
127 | $ | 2,700,000 | M | 83 | 73.5 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
128 | $ | 829,022 | F | 83 | 35.7 | Hartford Life and Annuity Insurance Company |
BBB+ |
||||||||||||||||||||
129 | $ | 1,500,000 | M | 83 | 91.4 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
130 | $ | 5,000,000 | M | 83 | 101.4 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
131 | $ | 7,600,000 | F | 83 | 109.8 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
132 | $ | 2,500,000 | F | 83 | 74.5 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
133 | $ | 2,500,000 | M | 83 | 71.2 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
134 | $ | 3,000,000 | M | 83 | 71.2 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
135 | $ | 500,000 | M | 83 | 51.7 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
136 | $ | 4,000,000 | F | 83 | 55.4 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
137 | $ | 3,000,000 | F | 83 | 54.8 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
138 | $ | 1,703,959 | M | 83 | 79.4 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
139 | $ | 500,000 | M | 83 | 27.7 | Great Southern Life Insurance Company |
N/A |
||||||||||||||||||||
140 | $ | 1,000,000 | M | 83 | 69.7 | Hartford Life and Annuity Insurance Company |
BBB+ |
||||||||||||||||||||
141 | $ | 3,500,000 | F | 83 | 120.5 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
142 | $ | 5,000,000 | M | 82 | 77.5 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
143 | $ | 500,000 | M | 82 | 113.2 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
144 | $ | 2,000,000 | M | 82 | 50.5 | National Life Insurance Company |
A |
||||||||||||||||||||
145 | $ | 4,200,000 | F | 82 | 140.3 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
146 | $ | 750,000 | M | 82 | 101.2 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
147 | $ | 5,000,000 | M | 82 | 85.5 | AXA Equitable Life Insurance Company |
A+ |
Face Amount |
Gender |
Age (ALB)(1) |
LE(2) |
Carrier |
S&P |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
148 | $ | 5,000,000 | M | 82 | 86.7 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
149 | $ | 1,500,000 | M | 82 | 87.4 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
150 | $ | 3,500,000 | F | 82 | 116.9 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
151 | $ | 3,000,000 | F | 82 | 106.8 | MetLife Investors USA Insurance Company |
AA- |
||||||||||||||||||||
152 | $ | 4,500,000 | M | 82 | 86.2 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
153 | $ | 2,275,000 | M | 82 | 103.6 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
154 | $ | 2,000,000 | M | 82 | 98.2 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
155 | $ | 3,500,000 | M | 82 | 84.5 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
156 | $ | 3,000,000 | M | 82 | 72.9 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
157 | $ | 1,500,000 | M | 82 | 34.9 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
158 | $ | 2,000,000 | F | 82 | 111.1 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
159 | $ | 10,000,000 | F | 82 | 68.3 | American National Insurance Company |
A |
||||||||||||||||||||
160 | $ | 500,000 | M | 82 | 34.6 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
161 | $ | 3,500,000 | F | 81 | 105.4 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
162 | $ | 1,000,000 | M | 81 | 80.9 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
163 | $ | 3,000,000 | M | 81 | 51.1 | U.S. Financial Life Insurance Company |
A+ |
||||||||||||||||||||
164 | $ | 1,500,000 | M | 81 | 67.2 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
165 | $ | 5,000,000 | M | 81 | 123.4 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
166 | $ | 1,900,000 | M | 81 | 77.9 | American National Insurance Company |
A |
||||||||||||||||||||
167 | $ | 500,000 | M | 81 | 56.6 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
168 | $ | 500,000 | M | 81 | 56.6 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
169 | $ | 250,000 | M | 81 | 42.7 | Jackson National Life Insurance Company |
AA |
||||||||||||||||||||
170 | $ | 5,000,000 | F | 81 | 87.6 | Sun Life Assurance Company of Canada (U.S.) |
BBB |
||||||||||||||||||||
171 | $ | 750,000 | M | 81 | 94.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
172 | $ | 1,995,000 | F | 81 | 93.4 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
173 | $ | 4,000,000 | M | 81 | 68.3 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
174 | $ | 1,250,000 | F | 81 | 73.3 | Columbus Life Insurance Company |
AA |
||||||||||||||||||||
175 | $ | 10,000,000 | M | 81 | 91.5 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
176 | $ | 2,300,000 | M | 81 | 30.3 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
177 | $ | 6,217,200 | F | 81 | 119.3 | Phoenix Life Insurance Company |
BB- |
||||||||||||||||||||
178 | $ | 2,500,000 | F | 81 | 84.5 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
179 | $ | 5,000,000 | F | 81 | 69.4 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
180 | $ | 5,000,000 | M | 81 | 88.3 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
181 | $ | 350,000 | M | 81 | 46.7 | Reassure America Life Insurance Company |
AA |
||||||||||||||||||||
182 | $ | 5,000,000 | M | 81 | 96.2 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
183 | $ | 3,000,000 | M | 80 | 80.2 | Protective Life Insurance Company |
AA- |
||||||||||||||||||||
184 | $ | 1,500,000 | M | 80 | 80.2 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
185 | $ | 2,000,000 | F | 80 | 130.2 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
186 | $ | 5,000,000 | M | 80 | 106.2 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
187 | $ | 550,000 | M | 80 | 118.2 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
188 | $ | 1,680,000 | F | 80 | 81.3 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
189 | $ | 1,000,000 | F | 80 | 111.8 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
190 | $ | 1,250,000 | M | 80 | 115.2 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
191 | $ | 1,000,000 | M | 80 | 79.5 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
192 | $ | 1,250,000 | F | 80 | 89.1 | Principal Life Insurance Company |
A+ |
||||||||||||||||||||
193 | $ | 2,000,000 | M | 80 | 52.2 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
194 | $ | 10,000,000 | M | 80 | 93.7 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
195 | $ | 5,000,000 | M | 80 | 86.8 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
196 | $ | 10,000,000 | M | 80 | 129.2 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
197 | $ | 2,000,000 | M | 80 | 83.6 | Ohio National Life Assurance Corporation |
AA- |
||||||||||||||||||||
198 | $ | 1,000,000 | M | 80 | 83.6 | Ohio National Life Assurance Corporation |
AA- |
||||||||||||||||||||
199 | $ | 3,000,000 | F | 80 | 122.1 | West Coast Life Insurance Company |
AA- |
Face Amount |
Gender |
Age (ALB)(1) |
LE(2) |
Carrier |
S&P |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
200 | $ | 7,000,000 | M | 80 | 101.7 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
201 | $ | 8,000,000 | M | 79 | 96.6 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
202 | $ | 2,000,000 | M | 79 | 38.7 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
203 | $ | 1,000,000 | M | 79 | 69.7 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
204 | $ | 2,000,000 | F | 79 | 105.2 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
205 | $ | 3,000,000 | M | 79 | 113.7 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
206 | $ | 1,750,000 | M | 79 | 97.6 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
207 | $ | 250,000 | M | 79 | 94.4 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
208 | $ | 2,000,000 | F | 79 | 103.5 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
209 | $ | 3,000,000 | M | 79 | 125.9 | Principal Life Insurance Company |
A+ |
||||||||||||||||||||
210 | $ | 5,000,000 | M | 79 | 109.1 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
211 | $ | 5,000,000 | M | 79 | 109.1 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
212 | $ | 3,000,000 | M | 78 | 55.4 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
213 | $ | 3,000,000 | M | 78 | 55.4 | Minnesota Life Insurance Company |
A+ |
||||||||||||||||||||
214 | $ | 3,000,000 | M | 78 | 55.4 | Prudential Life Insurance Company |
AA- |
||||||||||||||||||||
215 | $ | 3,000,000 | M | 78 | 106.3 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
216 | $ | 5,000,000 | M | 78 | 94.1 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
217 | $ | 5,000,000 | M | 78 | 94.1 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
218 | $ | 4,000,000 | M | 78 | 95.3 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
219 | $ | 3,601,500 | M | 78 | 110.6 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
220 | $ | 5,000,000 | M | 78 | 130.3 | Principal Life Insurance Company |
A+ |
||||||||||||||||||||
221 | $ | 5,000,000 | M | 78 | 106.8 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
222 | $ | 7,000,000 | M | 78 | 102.4 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
223 | $ | 476,574 | M | 78 | 87.9 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
224 | $ | 6,000,000 | M | 78 | 140.0 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
225 | $ | 130,000 | M | 78 | 62.7 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
226 | $ | 1,000,000 | M | 78 | 140.9 | Empire General Life Assurance Corporation |
AA- |
||||||||||||||||||||
227 | $ | 4,300,000 | F | 78 | 127.3 | American National Insurance Company |
A |
||||||||||||||||||||
228 | $ | 6,000,000 | M | 78 | 124.2 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
229 | $ | 750,000 | M | 78 | 85.4 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
230 | $ | 500,000 | M | 78 | 61.2 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
231 | $ | 5,000,000 | M | 77 | 93.6 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
232 | $ | 1,000,000 | M | 77 | 107.1 | Sun Life Assurance Company of Canada (U.S.) |
BBB |
||||||||||||||||||||
233 | $ | 5,000,000 | M | 77 | 105.4 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
234 | $ | 1,009,467 | M | 77 | 62.7 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
235 | $ | 4,000,000 | M | 77 | 63.9 | MetLife Investors USA Insurance Company |
AA- |
||||||||||||||||||||
236 | $ | 2,500,000 | M | 77 | 104.3 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
237 | $ | 2,500,000 | M | 77 | 104.3 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
238 | $ | 5,000,000 | M | 77 | 71.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
239 | $ | 2,250,000 | M | 77 | 111.0 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
240 | $ | 3,750,000 | M | 77 | 72.5 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
241 | $ | 1,000,000 | M | 77 | 127.8 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
242 | $ | 5,000,000 | F | 77 | 134.3 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
243 | $ | 3,000,000 | M | 77 | 112.4 | Principal Life Insurance Company |
A+ |
||||||||||||||||||||
244 | $ | 5,000,000 | M | 76 | 136.1 | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||||||||||
245 | $ | 500,000 | M | 76 | 82.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
246 | $ | 1,000,000 | M | 76 | 126.3 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
247 | $ | 2,840,000 | M | 76 | 116.1 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
248 | $ | 500,000 | F | 76 | 134.2 | Columbus Life Insurance Company |
AA |
||||||||||||||||||||
249 | $ | 750,000 | M | 76 | 19.7 | U.S. Financial Life Insurance Company |
A+ |
||||||||||||||||||||
250 | $ | 1,000,000 | F | 76 | 92.2 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
251 | $ | 1,750,000 | M | 76 | 78.1 | John Hancock Life Insurance Company (U.S.A) |
AA- |
Face Amount |
Gender |
Age (ALB)(1) |
LE(2) |
Carrier |
S&P |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
252 | $ | 5,000,000 | M | 76 | 121.2 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
253 | $ | 2,000,000 | F | 76 | 72.0 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
254 | $ | 4,000,000 | M | 75 | 83.9 | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||||||||||
255 | $ | 7,000,000 | F | 75 | 142.4 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
256 | $ | 1,000,000 | M | 75 | 101.2 | Pacific Life Insurance Company |
A+ |
||||||||||||||||||||
257 | $ | 490,620 | M | 75 | 104.5 | Ameritas Life Insurance Corporation |
A+ |
||||||||||||||||||||
258 | $ | 600,000 | M | 75 | 101.6 | Protective Life Insurance Company |
AA- |
||||||||||||||||||||
259 | $ | 5,000,000 | M | 75 | 76.0 | West Coast Life Insurance Company |
AA- |
||||||||||||||||||||
260 | $ | 5,000,000 | M | 74 | 169.1 | Prudential Life Insurance Company |
AA- |
||||||||||||||||||||
261 | $ | 3,000,000 | M | 74 | 72.0 | Aviva Life Insurance Company |
N/A |
||||||||||||||||||||
262 | $ | 8,000,000 | M | 74 | 122.6 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
263 | $ | 2,000,000 | F | 74 | 139.0 | Aviva Life Insurance Company |
N/A |
||||||||||||||||||||
264 | $ | 5,000,000 | M | 74 | 46.5 | Lincoln Benefit Life Company |
BBB+ |
||||||||||||||||||||
265 | $ | 850,000 | M | 74 | 83.0 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
266 | $ | 200,000 | M | 73 | 87.7 | ING Life Insurance and Annuity Company |
A- |
||||||||||||||||||||
267 | $ | 300,000 | M | 73 | 28.4 | Lincoln National Life Insurance Company |
AA- |
||||||||||||||||||||
268 | $ | 3,000,000 | F | 73 | 136.3 | General American Life Insurance Company |
AA- |
||||||||||||||||||||
269 | $ | 500,000 | M | 72 | 49.6 | Midland National Life Insurance Company |
A+ |
||||||||||||||||||||
270 | $ | 3,000,000 | M | 72 | 93.8 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
271 | $ | 1,000,000 | M | 72 | 87.2 | United of Omaha Life Insurance Company |
A+ |
||||||||||||||||||||
272 | $ | 2,000,000 | M | 72 | 118.6 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
273 | $ | 2,500,000 | M | 71 | 118.2 | American General Life Insurance Company |
A+ |
||||||||||||||||||||
274 | $ | 1,167,000 | M | 71 | 42.5 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
275 | $ | 2,000,000 | M | 70 | 124.0 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
276 | $ | 2,000,000 | M | 70 | 124.0 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
277 | $ | 600,000 | M | 70 | 106.9 | AXA Equitable Life Insurance Company |
A+ |
||||||||||||||||||||
278 | $ | 1,500,000 | M | 70 | 133.5 | Metropolitan Life Insurance Company |
AA- |
||||||||||||||||||||
279 | $ | 3,000,000 | M | 69 | 96.3 | John Hancock Life Insurance Company (U.S.A) |
AA- |
||||||||||||||||||||
280 | $ | 500,000 | M | 69 | 114.6 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
281 | $ | 500,000 | M | 69 | 114.6 | North American Company for Life And Health Insurance |
A+ |
||||||||||||||||||||
282 | $ | 2,000,000 | M | 67 | 136.9 | Transamerica Life Insurance Company |
AA- |
||||||||||||||||||||
283 | $ | 1,000,000 | M | 67 | 136.9 | Genworth Life Insurance Company |
A- |
||||||||||||||||||||
284 | $ | 156,538 | F | 66 | 128.6 | New York Life Insurance Company |
AA+ |
||||||||||||||||||||
285 | $ | 2,000,000 | M | 66 | 68.0 | MetLife Investors USA Insurance Company |
AA- |
||||||||||||||||||||
286 | $ | 2,000,000 | M | 66 | 68.0 | MetLife Investors USA Insurance Company |
AA- |
||||||||||||||||||||
$ | 771,939,841 |
(1) |
The insureds age is current as of the measurement date. |
(2) |
The insureds life expectancy estimate, other than for a small face value insurance policy benefit, is the average of two life expectancy estimates provided by independent third-party medical actuarial underwriting firms at the time of purchase, actuarially adjusted through the measurement date. Numbers in this column represent months. For more information, see disclosure under the Pricing Life Insurance Policies caption below. |
specializing in packaging the policies for presentation to participants in the secondary market. Their packaging includes obtaining medical records on the insured, life expectancy estimates from medical-actuarial firms, current insurance policy illustrations, and other information needed to properly evaluate the policy. The only parties able to evaluate the policies are regulated licensed providers. Once the providers have evaluated the policy, offers are made to the owner through a competitive auction process whereby brokers facilitate competing offers from providers, concurrently negotiating fees.
GWG applied this set of adjustments to all 21st Services life expectancy reports used in valuation of the portfolio as of December 31, 2012. At that time, the portfolio contained 211 policies on 194 insured lives. Of those 211 policies, 199 were valued using a 21st Services life expectancy report as part of the pricing life expectancy estimate calculation. While the analysis and adjustments were applied on an individual policy basis, the result was an average overall increase in the original life expectancy estimates of 8.67%. We have a standard practice of obtaining two third-party life expectancy estimates for each policy in our portfolio. As a result, the effective change in life expectancy on the portfolio as of December 31, 2012 was an average of approximately 4.33%, which resulted in an aggregate decrease in the fair value of our life settlements portfolio of $12.4 million as of December 31, 2012. Life expectancy reports by their very nature are estimates.
knowledge and resources, and is subject to numerous regulations. We have developed extensive experience and disciplines to work toward a stable and profitable portfolio. We update our actuarial projections each month for the portfolio based on the life expectancy estimates, premium payments made, and mortalities experienced. These data points combine to provide us with future forecasted cash flows with respect to our portfolio of life insurance assets. These forecasted future cash flows, along with our current financial position, are combined in a comprehensive model that includes detailed assumptions as to interest rates, financing costs, life insurance asset acquisitions, and capital markets activities. This comprehensive financial model enables us to closely monitor and manage our necessary capital reserves and attempt to project our future profitability.
Rank |
Policy Benefits |
Percentage of Policy Benefit Amt. |
Insurance Company |
Ins. Co. S&P Rating |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 |
$ | 123,380,000 | 15.98 | % | AXA Equitable Life Insurance Company |
A+ |
||||||||||||
2 |
$ | 85,920,000 | 11.13 | % | John Hancock Life Insurance Company (U.S.A.) |
AA- |
||||||||||||
3 |
$ | 73,920,000 | 9.58 | % | Transamerica Life Insurance Company |
AA- |
||||||||||||
4 |
$ | 56,215,000 | 7.28 | % | ING Life Insurance and Annuity Company |
A- |
||||||||||||
5 |
$ | 55,769,000 | 7.22 | % | Jefferson-Pilot Life Insurance Company |
AA- |
||||||||||||
6 |
$ | 42,735,000 | 5.54 | % | Massachusetts Mutual Life Insurance Company |
AA+ |
||||||||||||
7 |
$ | 39,550,000 | 5.12 | % | American General Life Insurance Company |
A+ |
||||||||||||
8 |
$ | 30,500,000 | 3.95 | % | Pacific Life Insurance Company |
A+ |
||||||||||||
9 |
$ | 28,450,000 | 3.69 | % | West Coast Life Insurance Company |
AA- |
||||||||||||
10 |
$ | 26,661,000 | 3.45 | % | Metropolitan Life Insurance Company |
AA- |
||||||||||||
States Where We Conduct Business Directly |
States Where We Conduct Business Through Other Licensed Providers |
|||||
---|---|---|---|---|---|---|
Alabama* |
Colorado |
|||||
Arizona |
Georgia |
|||||
Arkansas |
Indiana |
|||||
California |
Kentucky |
|||||
Connecticut |
Nevada |
|||||
Delaware |
New Jersey |
|||||
District
of Columbia* |
Oregon |
|||||
Florida |
Utah |
|||||
Illinois |
||||||
Iowa |
||||||
Kansas |
||||||
Louisiana |
||||||
Maine |
||||||
Maryland |
||||||
Massachusetts |
||||||
Michigan* |
||||||
Minnesota |
||||||
Mississippi |
||||||
Missouri* |
||||||
Nebraska |
||||||
New
Mexico* |
||||||
New
York |
||||||
North
Carolina |
||||||
Ohio |
||||||
Oklahoma |
||||||
Pennsylvania |
States Where We Conduct Business Directly |
States Where We Conduct Business Through Other Licensed Providers | |||||
---|---|---|---|---|---|---|
Rhode
Island |
||||||
South
Carolina* |
||||||
South
Dakota* |
||||||
Tennessee |
||||||
Texas |
||||||
Virginia |
||||||
Washington |
||||||
Wisconsin |
||||||
Wyoming* |
Name |
Age |
Positions |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Jon R. Sabes
|
47 | Chief Executive Officer and Director |
||||||||
Paul A.
Siegert |
75 | Director (Executive Chairman) |
||||||||
Steven F.
Sabes |
45 | President, Secretary and Director |
||||||||
William
Acheson |
49 | Chief Financial Officer |
||||||||
Jon Gangelhoff
|
56 | Chief Operating Officer |
||||||||
Jeffrey L.
McGregor |
60 | Director |
||||||||
Charles H.
Maguire III |
71 | Director |
||||||||
David H.
Abramson |
73 | Director |
||||||||
Shawn R.
Gensch |
45 | Director |
Name and Principal Position |
Salary |
Bonus (1) |
All Other Compensation (2) |
Total |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jon R. Sabes
|
2013 | $ | 350,000 | $ | 544,581 | $ | 16,905 | $ | 911,486 | |||||||||||||
Chief
Executive Officer |
2012 | $ | 350,000 | $ | 163,182 | $ | 0 | $ | 513,182 | |||||||||||||
Jon
Gangelhoff |
2013 | $ | 120,000 | $ | 57,276 | $ | 13,244 | $ | 190,520 | |||||||||||||
Chief
Financial Officer |
2012 | $ | 120,000 | $ | 28,244 | $ | 0 | $ | 148,244 | |||||||||||||
Paul A.
Siegert |
2013 | $ | 150,000 | $ | 54,236 | $ | 2,631 | $ | 206,867 | |||||||||||||
President and
Chairman of the Board |
2012 | $ | 150,000 | $ | 113,967 | $ | 0 | $ | 263,967 | |||||||||||||
Steven F.
Sabes |
2013 | $ | 150,000 | $ | 426,836 | $ | 11,063 | $ | 587,899 | |||||||||||||
COO and
Secretary |
2012 | $ | 150,000 | $ | 35,591 | $ | 0 | $ | 185,591 |
(1) |
In 2013, Messrs. Jon R. Sabes, Steven F. Sabes, and Paul A. Siegert each received a discretionary bonus related to the tax impact of the conversion of the Company from a limited liability company to a corporation. In this regard, Mr. Jon R. Sabes received a discretionary tax-related bonus of $436,700, Mr. Steven F. Sabes received a discretionary tax-related bonus of $380,600, and Mr. Paul A. Siegert received a discretionary tax-related bonus of $8,000. In addition, each named executive received a cash bonus under the Companys incentive compensation plan. Mr. Jon R. Sabes received a $107,881 cash bonus, Mr. Gangelhoff received a $57,276 cash bonus, Mr. Siegert received a $46,236 cash bonus, and Mr. Steven F. Sabes received a $46,236 cash bonus, under that incentive compensation plan. |
(2) |
All Other Compensation includes payment of unused and accrued vacation, and premiums paid by the Company that are reported on the named executives W-2 forms as a component of gross income. |
period after his termination of employment, regardless of the circumstances relating to that termination. If an executives employment is terminated by us without good cause or if the executive voluntarily resigns with good reason, then the executive will be entitled to (i) severance pay for a period of 12 months and (ii) reimbursement for health insurance premiums for his family if he elects continued coverage under COBRA.
Vested Shares |
Un-Vested Shares |
Total Shares |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jon Sabes
|
| 6,000 | 6,000 | |||||||||||
Steve Sabes
|
25,000 | 2,500 | 27,500 | |||||||||||
Paul Siegert
|
25,000 | 2,500 | 27,500 | |||||||||||
Jon
Gangelhoff |
50,000 | 27,000 | 77,000 | |||||||||||
100,000 | 38,000 | 138,000 |
Fees Earned or Paid in Cash |
||||||
---|---|---|---|---|---|---|
Directors Name |
2013 |
|||||
Paul A.
Siegert (Chairman) |
$ | 30,000 | ||||
Jon R. Sabes
|
$ | 30,000 | ||||
Steven F.
Sabes |
$ | 30,000 | ||||
Brian Tyrell
|
$ | 25,000 | ||||
Laurence
Zipkin |
$ | 25,000 | ||||
Kenneth Fink
|
$ | 25,000 | ||||
David H.
Abramson |
$ | 11,000 | ||||
Charles H.
Maguire III |
$ | 8,000 | ||||
Jeffrey L.
McGregor |
$ | 8,000 |
|
each person known by us to be the beneficial owner of more than five percent of our outstanding common stock |
|
each of our current directors |
|
each our current executive officers and any other persons identified as a named executive in the Summary Compensation Table above, and |
|
all our current executive officers and directors as a group. |
Name and Address |
Shares Beneficially Owned |
Percentage of Shares Beneficially Owned |
Shares Beneficially Owned After Offering (No Over- Allotment) |
Shares Benefically Owned After Offering (Full Over- Allotment) |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jon R.
Sabes (1) |
2,427,394 | 53.2 | % | 27.7 | % | 26.9 | % | |||||||||||
Steven S.
Sabes (2) |
2,386,247 | 52.0 | % | 27.1 | % | 26.4 | % | |||||||||||
Paul A.
Siegert (3) |
225,445 | 4.9 | % | 2.6 | % | 2.5 | % | |||||||||||
Jon
Gangelhoff (4) |
50,000 | 1.0 | % | 1.0 | % | 1.0 | % | |||||||||||
William B.
Acheson (5) |
2,500 | * | * | * | ||||||||||||||
David H.
Abramson (6) |
10,000 | * | * | * | ||||||||||||||
Jeffrey L.
McGregor (7) |
7,000 | * | * | * | ||||||||||||||
Charles H.
Maguire III (8) |
7,000 | * | * | * | ||||||||||||||
Shawn R.
Gensch (9) |
1,500 | * | * | * | ||||||||||||||
All
current directors and officers as a group |
4,628,000 | 98.7 | % | 52.0 | % | 50.6 | % |
* |
less than one percent. |
(1) |
Mr. Sabes is our Chief Executive Officer and a director of the Company. Shares reflected in the table include 1,092,276 shares held individually, 489,086 shares held by Opportunity Finance, LLC, a Minnesota limited liability company of which Mr. Sabes is a manager and member, 169,671 shares held by Jon Sabes 1992 Trust No.1, a trust of which Mr. Sabes is the beneficiary, 168,801 shares held by Jon Sabes 12.30.92 Trust, a trust of which Mr. Sabes is a beneficiary, 241,631 shares held by Jon Sabes1982 Trust, a trust of which Mr. Sabes is a beneficiary, and 163,737 shares held by Jon Sabes 1976 Trust, a trust of which Mr. Sabes is a beneficiary. Also 102,191 shares held by Mr. Sabes immediate family members. The trustees of each of the trusts are Robert W. Sabes, Steve F. Sabes and Ross A. Sabes. |
(2) |
Mr. Sabes is our President, Secretary and a director of the Company. Shares reflected in the table include 799,779 shares held individually, 489,086 shares held by Opportunity Finance, LLC, a Minnesota limited liability company of which Mr. Sabes is a manager and member, 521,158 shares held by SFS Trust 1982, a trust of which Mr. Sabes is the beneficiary, 350,779 shares held by SFS Trust 1992 Esther, a trust of which Mr. Sabes is a beneficiary, and 200,445 shares held by SFS Trust 1976, a trust of which Mr. Sabes is a beneficiary. The trustees of each of the trusts are Robert W. Sabes, Jon R. Sabes and Ross A. Sabes. The number of shares also include 25,000 of vested stock options granted pursuant to stock option agreement dated September 5, 2013 for 27,500 shares at a per-share exercise price of $8.28 vesting over a three-year period. |
(3) |
Mr. Siegert is a director of the Company (Executive Chairman). Shares reflected in the table include 200,445 shares held individually and 25,000 of vested stock options granted pursuant to stock option agreement dated September 5, 2013 for 27,500 shares at a per-share exercise price of $7.52 of which 25,000 vested immediately and 2,500 shall vest over a three-year period. |
(4) |
Mr. Gangelhoff is our Chief Operating Officer. Shares reflected in the table include 50,000 of vested stock options granted pursuant to stock option agreement dated September 5, 2013 for 77,000 shares at a per-share exercise price of $7.52 vesting over a three-year period. |
(5) |
Mr. Acheson is our Chief Financial Officer. Shares reflected in the table include 2,500 of vested stock options granted pursuant to a stock option agreement dated May 27, 2014 for 32,500 shares at a per-share exercise price of $7.52 and vesting over a three-year period. |
(6) |
Mr. Abramson is a director of the Company. Shares reflected in the table include 10,000 of vested stock options granted pursuant to a stock option agreement dated October 28, 2013 for 30,000 shares at a per-share exercise price of $7.52 and vesting quarterly over a three-year period. |
(7) |
Mr. McGregor is a director of the Company. Shares reflected in the table include 7,000 of vested stock options granted pursuant to a stock option agreement dated November 12, 2013 for 21,000 shares at a per-share exercise price of $7.52 and vesting quarterly over a three-year period. |
(8) |
Mr. Maguire is a director of the Company. Shares reflected in the table include 7,000 of vested stock options granted pursuant to a stock option agreement dated November 12, 2013 for 21,000 shares at a per-share exercise price of $7.52 and vesting quarterly over a three-year period. |
(9) |
Mr. Gensch is a director of the Company. Shares reflected in the table include 1,500 of vested stock options granted pursuant to a stock option agreement dated July 1, 2014 for 18,000 shares at a per-share exercise price of $7.46 and vesting quarterly over a three-year period. |
|
any breach of his or her duty of loyalty to us or our stockholders; |
|
acts or omissions not in good faith which involve intentional misconduct or a knowing violation of law; |
|
the payment of dividends or the redemption or purchase of stock in violation of Delaware law; or |
|
any transaction from which the director derived an improper personal benefit. |
|
1% of the number of shares of common stock then outstanding, which will equal approximately shares immediately after our initial public offering, or |
|
the average weekly trading volume of the common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. |
Underwriters |
Number of Shares |
|||||
---|---|---|---|---|---|---|
MLV &
Co. LLC |
||||||
Total:
|
1,600,000 |
Without exercise of option to purchase additional shares |
With full exercise of option to purchase additional shares |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Per Share
|
$ | $ | ||||||||
Total
|
$ | $ |
|
the information set forth in this prospectus and otherwise available to the representatives; |
|
our prospects and the history and prospects for the industry in which we compete; |
|
an assessment of our management; |
|
our prospects for future earnings; |
|
the general condition of the securities markets at the time of this offering; |
|
the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and |
|
other factors deemed relevant by the underwriters and us. |
Page | ||||||
---|---|---|---|---|---|---|
F-2 |
||||||
F-4 |
||||||
F-5 |
||||||
F-6 |
||||||
F-7 |
||||||
F-9 |
||||||
F-30 |
||||||
F-31 |
||||||
F-32 |
||||||
F-34 |
December 31, 2013 |
December 31, 2012 |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS |
|||||||||||
Cash and cash
equivalents |
$ | 33,449,793 | $ | 27,497,044 | |||||||
Restricted
cash |
5,832,970 | 2,093,092 | |||||||||
Due from
related parties |
| 8,613 | |||||||||
Investment in
life settlements, at fair value |
234,672,794 | 164,317,183 | |||||||||
Deferred
financing costs, net |
357,901 | 97,040 | |||||||||
Death
benefits receivable |
| 2,850,000 | |||||||||
Other assets
|
1,067,018 | 1,085,063 | |||||||||
TOTAL ASSETS
|
$ | 275,380,476 | $ | 197,948,035 | |||||||
LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) |
|||||||||||
LIABILITIES |
|||||||||||
Revolving
credit facility |
$ | 79,000,000 | $ | 71,000,000 | |||||||
Series I
Secured notes payable |
29,275,202 | 37,844,711 | |||||||||
Renewable
Secured Debentures |
131,646,062 | 55,718,950 | |||||||||
Accounts
payable |
839,869 | 470,059 | |||||||||
Interest
payable |
7,209,408 | 3,477,320 | |||||||||
Other accrued
expenses |
504,083 | 1,291,499 | |||||||||
Deferred
taxes, net |
7,675,174 | 5,501,407 | |||||||||
TOTAL
LIABILITIES |
256,149,798 | 175,303,946 | |||||||||
COMMITMENTS AND CONTINGENCIES (NOTES 14 AND 15) |
|||||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK (par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,368,109 and 3,361,076; liquidation preference of $25,261,000 and $25,208,000 on December 31, 2013 and 2012, respectively) |
24,722,693 | 23,905,878 | |||||||||
STOCKHOLDERS EQUITY (DEFICIT) |
|||||||||||
Common stock
(par value $0.001: shares authorized 210,000,000; shares issued and outstanding 4,562,000 and 4,994,500 on December 31, 2013 and 2012)
|
4,562 | 4,995 | |||||||||
Additional
paid-in capital |
2,942,000 | 6,976,838 | |||||||||
Accumulated
deficit |
(8,438,577 | ) | (8,243,622 | ) | |||||||
TOTAL
STOCKHOLDERS EQUITY (DEFICIT) |
(5,492,015 | ) | (1,261,789 | ) | |||||||
TOTAL
LIABILITIES & EQUITY (DEFICIT) |
$ | 275,380,476 | $ | 197,948,035 |
Year Ended |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
December 31, 2013 |
December 31, 2012 |
||||||||||
REVENUE |
|||||||||||
Gain on life
settlements, net |
$ | 29,513,642 | $ | 17,436,743 | |||||||
Gain upon
termination of agreement with Athena Securities Ltd. |
$ | 3,252,400 | | ||||||||
Interest and
other income |
298,732 | 89,055 | |||||||||
TOTAL
REVENUE |
33,064,774 | 17,525,798 | |||||||||
EXPENSES |
|||||||||||
Interest
expense |
20,762,644 | 10,878,627 | |||||||||
Employee
compensation and benefits |
5,043,848 | 2,903,373 | |||||||||
Legal and
professional fees |
1,754,209 | 1,076,694 | |||||||||
Other
expenses |
3,525,261 | 2,486,813 | |||||||||
TOTAL
EXPENSES |
31,085,962 | 17,345,507 | |||||||||
INCOME BEFORE
INCOME TAXES |
1,978,812 | 180,291 | |||||||||
INCOME TAX
EXPENSE |
2,173,767 | 1,193,190 | |||||||||
NET
LOSS |
(194,955 | ) | (1,012,899 | ) | |||||||
Accretion of
preferred stock to liquidation value |
(806,624 | ) | (1,578,405 | ) | |||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS |
$ | (1,001,579 | ) | $ | (2,591,304 | ) | |||||
NET LOSS PER
COMMON SHARE (BASIC AND DILUTED) |
|||||||||||
Net
loss |
$(0.04 | ) | $(0.20 | ) | |||||||
Accretion of
preferred stock to liquidation value |
$(0.17 | ) | $(0.32 | ) | |||||||
Net loss per
share attributable to common shareholders |
$(0.21 | ) | $(0.52 | ) | |||||||
WEIGHTED
AVERAGE SHARES OUTSTANDING |
|||||||||||
Basic and
diluted |
4,758,699 | 4,994,500 |
Common Shares |
Common Stock (par) |
Additional Paid-in Capital |
Accumulated Deficit |
Total Equity |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance,
December 31, 2011 |
4,994,500 | $ | 4,995 | $8,174,297 | $ | (7,230,723 | ) | $ | 948,569 | |||||||||||||
Net loss
|
| | | (1,012,899 | ) | (1,012,899 | ) | |||||||||||||||
Issuance of
warrants to purchase common stock |
| | 380,946 | | 380,946 | |||||||||||||||||
Accretion of
preferred stock to liquidation value |
| | (1,578,405 | ) | | (1,578,405 | ) | |||||||||||||||
Balance,
December 31, 2012 |
4,994,500 | 4,995 | 6,976,838 | (8,243,622 | ) | (1,261,789 | ) | |||||||||||||||
Net loss
|
| | | (194,955 | ) | (194,955 | ) | |||||||||||||||
Repurchase of
common stock |
(432,500 | ) | (433 | ) | (3,251,967 | ) | | (3,252,400 | ) | |||||||||||||
Stock-based
compensation |
| | 23,753 | | 23,753 | |||||||||||||||||
Accretion of
preferred stock to liquidation value |
| | (806,624 | ) | | (806,624 | ) | |||||||||||||||
Balance,
December 31, 2013 |
4,562,000 | $ | 4,562 | $2,942,000 | $ | (8,438,577 | ) | $ | (5,492,015 | ) |
Year Ended |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
December 31, 2013 |
December 31, 2012 |
||||||||||
CASH FLOWS
FROM OPERATING ACTIVITIES |
|||||||||||
Net loss
|
$ | (194,955 | ) | $ | (1,012,899 | ) | |||||
Adjustments
to reconcile net loss to net cash flows used in operating activities: |
|||||||||||
Gain on life
settlements |
(39,337,542 | ) | (27,856,374 | ) | |||||||
Amortization
of deferred financing and issuance costs |
2,470,390 | 1,908,930 | |||||||||
Deferred
income taxes |
2,173,767 | 1,193,190 | |||||||||
Convertible,
redeemable preferred stock issued in lieu of cash dividends |
623,899 | 567,478 | |||||||||
Convertible,
redeemable preferred stock dividends payable |
255 | 338,695 | |||||||||
Gain upon
termination of agreement with Athena Securities Ltd. |
(3,252,400 | ) | | ||||||||
(Increase)
decrease in operating assets: |
|||||||||||
Due from
related parties |
8,613 | (6,348 | ) | ||||||||
Death
benefits receivable |
2,850,000 | (2,850,000 | ) | ||||||||
Other assets
|
(566,418 | ) | (869,165 | ) | |||||||
Increase
(decrease) in operating liabilities: |
|||||||||||
Accounts
payable |
369,809 | (257,708 | ) | ||||||||
Interest
payable |
3,418,432 | 1,744,599 | |||||||||
Other accrued
expenses |
50,642 | (69,292 | ) | ||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES |
(31,385,508 | ) | (27,168,894 | ) | |||||||
CASH FLOWS
FROM INVESTING ACTIVITIES |
|||||||||||
Investment in
life settlements |
(34,997,500 | ) | (15,067,495 | ) | |||||||
Proceeds from
settlement of life settlements |
4,563,896 | 1,067,210 | |||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES |
(30,433,604 | ) | (14,000,285 | ) | |||||||
CASH FLOWS
FROM FINANCING ACTIVITIES |
|||||||||||
Net proceeds
from revolving credit facility |
8,000,000 | 11,000,000 | |||||||||
Payments for
redemption of Series I Secured notes payable |
(8,671,624 | ) | (7,477,197 | ) | |||||||
Proceeds from
issuance of Renewable Secured Debentures |
85,260,976 | 58,553,280 | |||||||||
Payment of
deferred issuance costs for Renewable Secured Debentures |
(4,320,542 | ) | (3,024,545 | ) | |||||||
Payments for
redemption of Renewable Secured Debentures |
(8,143,363 | ) | (112,500 | ) | |||||||
Proceeds from
(uses of) restricted cash |
(3,739,878 | ) | 2,701,210 | ||||||||
Issuance
(redemption) of convertible, redeemable preferred stock |
(613,708 | ) | 6,414,273 | ||||||||
Payments of
issuance cost for convertible, redeemable preferred stock |
| (1,266,647 | ) | ||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES |
67,771,861 | 66,787,874 | |||||||||
NET INCREASE
IN CASH AND CASH EQUIVALENTS |
5,952,749 | 25,618,695 | |||||||||
CASH AND
CASH EQUIVALENTS |
|||||||||||
BEGINNING OF
PERIOD |
27,497,044 | 1,878,349 | |||||||||
END OF PERIOD
|
$ | 33,449,793 | $ | 27,497,044 |
Year Ended |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
December 31, 2013 |
December 31, 2012 |
||||||||||
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION |
|||||||||||
Interest and
preferred dividends paid |
$ | 13,627,000 | $ | 6,280,000 | |||||||
NON-CASH
INVESTING AND FINANCING ACTIVITIES |
|||||||||||
Non-cash
conversion of Series I Secured notes |
$ | 912,000 | $ | 4,220,000 | |||||||
Non-cash
conversion of accrued interest payable on Series I Secured notes |
$ | | $ | 6,000 | |||||||
Warrants
issued to purchase common stock |
$ | | $ | 381,000 | |||||||
Options
issued to purchase common stock |
$ | 24,000 | $ | | |||||||
Accrued
interest payable on Series I Secured notes added to principal |
$ | 185,000 | $ | 142,000 | |||||||
Accrued
interest payable on Renewable Secured Debentures added to principal |
$ | 141,000 | $ | 13,000 | |||||||
Unsettled
life settlements included in accounts payable |
$ | | $ | 292,000 |
1) |
Receipt of death notice or verified obituary of insured |
2) |
Sale of policy and filing of change of ownership forms and receipt of payment |
As of December 31, 2013 |
As of December 31, 2012 |
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Years Ending December 31, |
Number of Contracts |
Estimated Fair Value |
Face Value |
Number of Contracts |
Estimated Fair Value |
Face Value |
|||||||||||||||||||||
2014
|
| $ | | $ | | | $ | | $ | | |||||||||||||||||
2015
|
4 | 5,065,000 | 6,750,000 | | | | |||||||||||||||||||||
2016
|
8 | 8,174,000 | 13,750,000 | 2 | 1,163,000 | 2,000,000 | |||||||||||||||||||||
2017
|
25 | 33,345,000 | 63,916,000 | 13 | 11,608,000 | 22,229,000 | |||||||||||||||||||||
2018
|
33 | 37,243,000 | 80,318,000 | 17 | 21,155,000 | 53,439,000 | |||||||||||||||||||||
2019
|
34 | 32,844,000 | 89,295,000 | 31 | 28,252,000 | 75,668,000 | |||||||||||||||||||||
2020
|
34 | 27,741,000 | 75,644,000 | 35 | 26,947,000 | 84,579,000 | |||||||||||||||||||||
Thereafter
|
125 | 90,261,000 | 410,975,000 | 113 | 75,192,000 | 334,331,000 | |||||||||||||||||||||
Totals
|
263 | $ | 234,673,000 | $ | 740,648,000 | 211 | $ | 164,317,000 | $ | 572,246,000 |
2013 |
2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Change in
fair value |
$ | 39,338,000 | $ | 27,856,000 | ||||||
Premiums and
other annual fees |
(21,860,000 | ) | (16,702,000 | ) | ||||||
Policy
maturities |
12,036,000 | 6,283,000 | ||||||||
Gain on life
settlements, net |
$ | 29,514,000 | $ | 17,437,000 |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
2014
|
$ | 22,739,000 | ||||
2015
|
25,056,000 | |||||
2016
|
27,508,000 | |||||
2017
|
30,653,000 | |||||
2018
|
33,509,000 | |||||
$ | 139,465,000 |
|
Level 1 Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. |
|
Level 2 Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. |
|
Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
2013 |
2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Beginning
balance |
$ | 164,317,000 | $ | 122,169,000 | ||||||
Purchases
|
35,582,000 | 15,359,000 | ||||||||
Maturities
(acquisition cost) |
(4,564,000 | ) | (1,067,000 | ) | ||||||
Gross
unrealized gains |
39,338,000 | 28,055,000 | ||||||||
Gross
unrealized losses |
| (199,000 | ) | |||||||
Ending
balance |
$ | 234,673,000 | $ | 164,317,000 |
As of December 31, 2013 |
As of December 31, 2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Weighted
average age of insured |
82.1 | 81.3 | ||||||||
Weighted
average life expectancy, months* |
87.0 | 91.6 | ||||||||
Average face
amount per policy |
$ | 2,816,000 | $ | 2,712,064 | ||||||
Discount
rate |
11.69 | % | 12.08 | % |
* |
Standard life expectancy as adjusted for insureds specific circumstances. |
Change in life expectancy |
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
plus 8 months |
minus 8 months |
plus 4 months |
minus 4 months |
||||||||||||||||
Investment in
life policies |
|||||||||||||||||||
December 31,
2013 |
$ | (34,382,000 | ) | $ | 36,152,000 | $ | (17,417,000 | ) | $ | 17,865,000 | |||||||||
December 31,
2012 |
$ | (24,072,000 | ) | $ | 25,268,000 | $ | (12,185,000 | ) | $ | 12,484,000 |
Change in discount rate |
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
plus 2% |
minus 2% |
plus 1% |
minus 1% |
||||||||||||||||
Investment in
life policies |
|||||||||||||||||||
December 31,
2013 |
$ | (22,944,000 | ) | $ | 27,063,000 | $ | (11,933,000 | ) | $ | 12,959,000 | |||||||||
December 31,
2012 |
$ | (16,811,000 | ) | $ | 19,978,000 | $ | (8,759,000 | ) | $ | 9,547,000 |
Month issued |
Warrants issued |
Fair value per share |
Risk free rate |
Volatility |
Term |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
December 2011
|
68,937 | $ | 0.22 | 0.42 | % | 25.25 | % | 3 | years | |||||||||||||
March 2012
|
38,130 | $ | 0.52 | 0.38 | % | 36.20 | % | 3 | years | |||||||||||||
June 2012
|
161,841 | $ | 1.16 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
July 2012
|
144,547 | $ | 1.16 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
September 2012
|
2,500 | $ | 0.72 | 0.31 | % | 40.49 | % | 3 | years | |||||||||||||
415,955 |
|
changing its corporate name, offices, and jurisdiction of incorporation |
|
changing any deposit accounts or payment instructions to insurers; |
|
changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect; |
|
merging or consolidating with, or selling all or substantially all of its assets to, any third party; |
|
selling any collateral or creating or permitting to exist any adverse claim upon any collateral; |
|
engaging in any other business or activity than that contemplated by the Agreement; |
|
incurring or guaranteeing any debt for borrowed money; |
|
amending the Companys certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event; |
|
removing an independent director on the board of directors except for cause or with the consent of the lender; or |
|
making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action. |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
2014
|
$ | 16,111,000 | ||||
2015
|
6,700,000 | |||||
2016
|
2,030,000 | |||||
2017
|
4,085,000 | |||||
2018
|
754,000 | |||||
Thereafter
|
64,000 | |||||
$ | 29,744,000 |
Years Ending December 31, |
||||||
---|---|---|---|---|---|---|
2013
|
$ | 34,258,000 | ||||
2014
|
41,509,000 | |||||
2015
|
29,152,000 | |||||
2016
|
7,667,000 | |||||
2017
|
5,381,000 | |||||
Thereafter
|
16,924,000 | |||||
$ | 134,891,000 |
|
Up to 33% of the holders unredeemed shares one year after issuance: |
|
Up to 66% of the holders unredeemed shares two years after issuance; and |
|
Up to 100% of the holders unredeemed shares three years after issuance. |
Income tax provision: |
2013 |
2012 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Deferred: |
||||||||||
Federal
|
$ | 1,826,000 | $ | 1,002,000 | ||||||
State
|
348,000 | 191,000 | ||||||||
Total income
tax expense |
$ | 2,174,000 | $ | 1,193,000 |
2013 |
2012 |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statutory federal income tax |
$ | 673,000 | 34.0 | % | $ | 61,000 | 34.0 | % | |||||||||||
State
income taxes, net of federal benefit |
298,000 | 15.1 | % | 165,000 | 91.2 | % | |||||||||||||
Series
A preferred stock dividends |
860,000 | 43.4 | % | 757,000 | 420.1 | % | |||||||||||||
Other
permanent differences |
343,000 | 17.3 | % | 210,000 | 116.5 | % | |||||||||||||
Total
income tax expense |
$ | 2,174,000 | 109.8 | % | $ | 1,193,000 | 661.8 | % |
2013 |
2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Deferred tax
assets: |
||||||||||
Athena
Securities Group, LTD, advisory services |
$ | | $ | 1,455,000 | ||||||
Note
receivable from related party |
2,023,000 | 2,023,000 | ||||||||
Net operating
loss carryforwards |
2,596,000 | 1,671,000 | ||||||||
Other assets
|
164,000 | 20,000 | ||||||||
Subtotal
|
4,783,000 | 5,169,000 | ||||||||
Valuation
allowance |
(2,164,000 | ) | (2,023,000 | ) | ||||||
Net deferred
tax asset |
2,619,000 | 3,146,000 | ||||||||
Deferred tax
liabilities: |
||||||||||
Investment in
life settlements |
(10,294,000 | ) | (8,647,000 | ) | ||||||
Net deferred
tax liability |
$ | (7,675,000 | ) | $ | (5,501,000 | ) |
Grant Date |
Exercise Price |
Shares |
Vesting |
Binomial Value |
Forfeiture Factor |
Compensation Expense |
||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/5/2013 | $ | 7.46 | 1,250.00 | Immediate |
0.36 | 0.87 | 391.50 | * | ||||||||||||||||||
9/5/2013 | $ | 7.52 | 142,500.00 | Immediate |
0.36 | 0.87 | 44,631.00 | * | ||||||||||||||||||
9/5/2013 | $ | 8.28 | 25,000.00 | Immediate |
0.36 | 0.87 | 7,830.00 | * | ||||||||||||||||||
9/5/2013 | $ | 7.46 | 1,500.00 | 1
year |
0.36 | 0.85 | 459.00 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 44,338.50 | 1
year |
0.36 | 0.85 | 13,567.58 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 2,833.50 | 1
year |
0.36 | 0.85 | 867.05 | |||||||||||||||||||
9/5/2013 | $ | 7.46 | 1,500.00 | 2
years |
0.6 | 0.7225 | 650.25 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 44,333.00 | 2
years |
0.6 | 0.7225 | 19,218.36 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 2,833.50 | 2
years |
0.6 | 0.7225 | 1,228.32 | |||||||||||||||||||
9/5/2013 | $ | 7.46 | 1,500.00 | 3
years |
0.82 | 0.6141 | 755.34 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 44,328.50 | 3
years |
0.82 | 0.6141 | 22,322.15 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 2,833.00 | 3
years |
0.82 | 0.6141 | 1,426.59 | |||||||||||||||||||
9/30/2013 | $ | 7.52 | 4,000.00 | Immediate |
0.66 | 0.87 | 2,296.80 | * | ||||||||||||||||||
10/28/2013 | $ | 7.52 | 4,250.00 | Immediate |
0.66 | 0.87 | 2,440.35 | * | ||||||||||||||||||
10/28/2013 | $ | 7.52 | 17,000.00 | 1
year |
0.66 | 0.85 | 9,537.00 | |||||||||||||||||||
10/28/2013 | $ | 7.52 | 17,000.00 | 2
years |
0.92 | 0.7225 | 11,299.90 | |||||||||||||||||||
10/28/2013 | $ | 7.52 | 12,750.00 | 3
years |
1.14 | 0.6141 | 8,925.94 | |||||||||||||||||||
11/11/2013 | $ | 7.52 | 4,167.00 | 1
year |
0.66 | 0.85 | 2,337.69 | |||||||||||||||||||
11/11/2013 | $ | 7.52 | 4,166.50 | 2
years |
0.92 | 0.7225 | 2,769.47 | |||||||||||||||||||
11/11/2013 | $ | 7.52 | 4,166.50 | 3
years |
1.14 | 0.6141 | 2,916.86 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 1,750.00 | Immediate |
0.66 | 0.87 | 1,004.85 | * | ||||||||||||||||||
11/12/2013 | $ | 7.52 | 7,000.00 | 1
year |
0.66 | 0.85 | 3,927.00 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 7,000.00 | 2
years |
0.92 | 0.7225 | 4,652.90 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 5,250.00 | 3
years |
1.14 | 0.6141 | 3,675.39 | |||||||||||||||||||
12/12/2013 | $ | 7.52 | 30,000.00 | Immediate |
0.66 | 0.87 | 17,226.00 | * | ||||||||||||||||||
433,250.00 |
* |
Amounts reflected in current period earnings. |
Vested |
Un-vested |
Total |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance as of
December 31, 2012 |
| | | |||||||||||
Granted
during the year |
208,750 | 224,500 | 433,250 | |||||||||||
Exercised
during the year |
| | | |||||||||||
Forfeited
during the year |
(13,750 | ) | (14,250 | ) | (28,000 | ) | ||||||||
Expired
during the year |
| | | |||||||||||
Balance as of
December 31, 2013 |
195,000 | 210,250 | 405,250 |
December 31, 2013 |
December 31, 2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
NET
LOSS |
$ | (194,955 | ) | $ | (1,012,899 | ) | ||||
Accretion of
preferred stock to liquidation value |
(806,624 | ) | (1,578,405 | ) | ||||||
LOSS
ATTRIBUTABE TO COMMON SHAREHOLDERS |
$ | (1,001,579 | ) | $ | (2,591,304 | ) | ||||
Basic and
diluted weighted average shares outstanding |
4,758,699 | 4,999,500 | ||||||||
NET LOSS PER
COMMON SHARE (BASIC AND DILUTED) |
||||||||||
Net
loss |
$(0.04 | ) | $(0.20 | ) | ||||||
Accretion of
value to preferred stock |
$(0.17 | ) | $(0.32 | ) | ||||||
Net loss
attributable to common shareholders |
$(0.21 | ) | $(0.52 | ) |
2014
|
104,000 | |||||
2015
|
70,000 | |||||
Total
|
$ | 174,000 |
December 31, 2013 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS |
||||||||||||||||||||||
Cash and cash
equivalents |
$ | 32,711,636 | $ | 738,157 | $ | | $ | | $ | 33,449,793 | ||||||||||||
Restricted
cash |
| 1,420,000 | 4,412,970 | | 5,832,970 | |||||||||||||||||
Investment in
life settlements, at fair value |
| | 234,672,794 | | 234,672,794 | |||||||||||||||||
Deferred
financing costs, net |
| | 357,901 | | 357,901 | |||||||||||||||||
Other assets
|
381,883 | 484,510 | 200,625 | | 1,067,018 | |||||||||||||||||
Investment in
subsidiaries |
129,839,241 | 159,798,490 | | (289,637,731 | ) | | ||||||||||||||||
TOTAL ASSETS
|
$ | 162,932,760 | $ | 162,441,157 | $ | 239,644,290 | $ | (289,637,731 | ) | $ | 275,380,476 | |||||||||||
LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
LIABILITIES |
||||||||||||||||||||||
Revolving
credit facility |
$ | | $ | | $ | 79,000,000 | $ | | $ | 79,000,000 | ||||||||||||
Series I
Secured notes payable |
| 29,275,202 | | | 29,275,202 | |||||||||||||||||
Renewable
Secured Debentures |
131,646,062 | | | | 131,646,062 | |||||||||||||||||
Accounts
payable |
233,214 | 106,655 | 500,000 | | 839,869 | |||||||||||||||||
Interest
payable |
3,806,820 | 3,065,465 | 337,123 | | 7,209,408 | |||||||||||||||||
Other accrued
expenses |
340,812 | 154,594 | 8,677 | | 504,083 | |||||||||||||||||
Deferred
taxes |
7,675,174 | | | | 7,675,174 | |||||||||||||||||
TOTAL
LIABILITIES |
143,702,082 | 32,601,916 | 79,845,800 | | 256,149,798 | |||||||||||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK |
24,722,693 | | | | 24,722,693 | |||||||||||||||||
STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
Member
capital |
| 129,839,241 | 159,798,490 | (289,637,731 | ) | | ||||||||||||||||
Common stock
|
4,562 | | | | 4,562 | |||||||||||||||||
Additional
paid-in capital |
2,942,000 | | | | 2,942,000 | |||||||||||||||||
Accumulated
deficit |
(8,438,577 | ) | | | | (8,438,577 | ) | |||||||||||||||
TOTAL
STOCKHOLDERS EQUITY (DEFICIT) |
(5,492,015 | ) | 129,839,241 | 159,798,490 | (289,637,731 | ) | (5,492,015 | ) | ||||||||||||||
TOTAL
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) |
$ | 162,932,760 | $ | 162,441,157 | $ | 239,644,290 | $ | (289,637,731 | ) | $ | 275,380,476 |
December 31, 2012 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS |
||||||||||||||||||||||
Cash and cash
equivalents |
$ | 25,035,579 | $ | 2,461,465 | $ | | $ | | $ | 27,497,044 | ||||||||||||
Restricted
cash |
| 1,748,700 | 344,392 | | 2,093,092 | |||||||||||||||||
Due from
related parties |
| 8,613 | | | 8,613 | |||||||||||||||||
Investment in
life settlements, at fair value |
| | 164,317,183 | | 164,317,183 | |||||||||||||||||
Deferred
financing costs, net |
| | 97,040 | | 97,040 | |||||||||||||||||
Death
benefits receivable |
| | 2,850,000 | | 2,850,000 | |||||||||||||||||
Other assets
|
96,994 | 202,979 | 785,090 | | 1,085,063 | |||||||||||||||||
Investment in
subsidiaries |
60,608,585 | 96,914,613 | | (157,523,198 | ) | | ||||||||||||||||
TOTAL ASSETS
|
$ | 85,741,158 | $ | 101,336,370 | $ | 168,393,705 | $ | (157,523,198 | ) | $ | 197,948,035 | |||||||||||
LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
LIABILITIES |
||||||||||||||||||||||
Revolving
credit facility |
$ | | $ | | $ | 71,000,000 | $ | | $ | 71,000,000 | ||||||||||||
Series I
Secured notes payable |
| 37,844,711 | | | 37,844,711 | |||||||||||||||||
Renewable
Secured Debentures |
55,718,950 | | | | 55,718,950 | |||||||||||||||||
Accounts
payable |
73,084 | 104,975 | 292,000 | | 470,059 | |||||||||||||||||
Interest
payable |
905,017 | 2,444,097 | 128,206 | | 3,477,320 | |||||||||||||||||
Other accrued
expenses |
898,611 | 382,522 | 10,366 | | 1,291,499 | |||||||||||||||||
Deferred
taxes |
5,501,407 | | | | 5,501,407 | |||||||||||||||||
TOTAL
LIABILITIES |
63,097,069 | 40,776,305 | 71,430,572 | | 175,303,946 | |||||||||||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK |
23,905,878 | | | | 23,905,878 | |||||||||||||||||
STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
Member
capital |
| 60,560,065 | 96,963,133 | (157,523,198 | ) | | ||||||||||||||||
Common stock
|
4,995 | | | | 4,995 | |||||||||||||||||
Additional
paid-in capital |
6,976,838 | | | | 6,976,838 | |||||||||||||||||
Accumulated
deficit |
(8,243,622 | ) | | | | (8,243,622 | ) | |||||||||||||||
TOTAL
STOCKHOLDERS EQUITY (DEFICIT) |
(1,261,789 | ) | 60,560,065 | 96,963,133 | (157,523,198 | ) | (1,261,789 | ) | ||||||||||||||
TOTAL
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) |
$ | 85,741,158 | $ | 101,336,370 | $ | 168,393,705 | $ | (157,523,198 | ) | $ | 197,948,035 |
For the year ended December 31, 2013 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE |
||||||||||||||||||||||
Contract
servicing fees |
$ | | $ | 3,710,737 | $ | | $ | (3,710,737 | ) | $ | | |||||||||||
Gain on life
settlements, net |
| | 29,513,642 | | 29,513,642 | |||||||||||||||||
Gain upon
termination of agreement with Athena Securities Ltd. |
$ | 3,252,400 | | | | $ | 3,252,400 | |||||||||||||||
Interest and
other income |
81,931 | 2,612,420 | 79,767 | (2,475,386 | ) | 298,732 | ||||||||||||||||
TOTAL REVENUE
|
3,334,331 | 6,323,157 | 29,593,409 | (6,186,123 | ) | 33,064,774 | ||||||||||||||||
EXPENSES |
||||||||||||||||||||||
Origination
and servicing fees |
| | 3,710,737 | (3,710,737 | ) | | ||||||||||||||||
Interest
expense |
11,800,718 | 3,684,811 | 5,277,115 | | 20,762,644 | |||||||||||||||||
Employee
compensation and benefits |
3,424,383 | 1,619,465 | | | 5,043,848 | |||||||||||||||||
Legal and
professional fees |
1,206,520 | 514,728 | 32,961 | | 1,754,209 | |||||||||||||||||
Other
expenses |
2,004,636 | 1,463,084 | 2,532,927 | (2,475,386 | ) | 3,525,261 | ||||||||||||||||
TOTAL
EXPENSES |
18,436,257 | 7,282,088 | 11,553,740 | (6,186,123 | ) | 31,085,962 | ||||||||||||||||
INCOME (LOSS)
BEFORE EQUITY IN INCOME OF SUBSIDIARIES |
(15,101,926 | ) | (958,931 | ) | 18,039,669 | | 1,978,812 | |||||||||||||||
EQUITY IN
INCOME OF SUBSIDIARIES |
17,080,738 | 18,088,189 | | (35,168,927 | ) | | ||||||||||||||||
NET INCOME
BEFORE INCOME TAXES |
1,978,812 | 17,129,258 | 18,039,669 | (35,168,927 | ) | 1,978,812 | ||||||||||||||||
INCOME TAX
EXPENSE |
2,173,767 | | | | 2,173,767 | |||||||||||||||||
NET INCOME
(LOSS) |
(194,955 | ) | 17,129,258 | 18,039,669 | (35,168,927 | ) | (194,955 | ) | ||||||||||||||
Accretion of
preferred stock to liquidation value |
(806,624 | ) | | | | (806,624 | ) | |||||||||||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS |
$ | (1,001,579 | ) | $ | 17,129,258 | $ | 18,039,669 | $ | (35,168,927 | ) | $ | (1,001,579 | ) |
For the year ended December 31, 2012 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE |
||||||||||||||||||||||
Contract
servicing fees |
$ | | $ | 2,539,437 | $ | | $ | (2,539,437 | ) | $ | | |||||||||||
Gain on life
settlements, net |
| | 17,436,743 | | 17,436,743 | |||||||||||||||||
Interest and
other income |
42,668 | 223,311 | 42,747 | (219,671 | ) | 89,055 | ||||||||||||||||
TOTAL REVENUE
|
42,668 | 2,762,748 | 17,479,490 | (2,759,108 | ) | 17,525,798 | ||||||||||||||||
EXPENSES |
||||||||||||||||||||||
Origination
and servicing fees |
| | 2,539,437 | (2,539,437 | ) | | ||||||||||||||||
Interest
expense |
4,311,719 | 4,833,058 | 1,953,521 | (219,671 | ) | 10,878,627 | ||||||||||||||||
Employee
compensation and benefits |
| 2,903,373 | | | 2,903,373 | |||||||||||||||||
Legal and
professional fees |
899,588 | 162,323 | 14,783 | | 1,076,694 | |||||||||||||||||
Other
expenses |
937,562 | 1,496,752 | 52,499 | | 2,486,813 | |||||||||||||||||
TOTAL
EXPENSES |
6,148,869 | 9,395,506 | 4,560,240 | (2,759,108 | ) | 17,345,507 | ||||||||||||||||
INCOME (LOSS)
BEFORE EQUITY IN INCOME OF SUBSIDIARIES |
(6,106,201 | ) | (6,632,758 | ) | 12,919,250 | | 180,291 | |||||||||||||||
EQUITY IN
INCOME OF SUBSIDIARIES |
6,286,492 | 13,035,698 | | (19,322,190 | ) | | ||||||||||||||||
NET INCOME
BEFORE INCOME TAXES |
180,291 | 6,402,940 | 12,919,250 | (19,322,190 | ) | 180,291 | ||||||||||||||||
INCOME TAX
EXPENSE |
1,193,190 | | | | 1,193,190 | |||||||||||||||||
NET INCOME
(LOSS) |
(1,012,899 | ) | 6,402,940 | 12,919,250 | (19,322,190 | ) | (1,012,899 | ) | ||||||||||||||
Accretion of
preferred stock to liquidation value |
(1,578,405 | ) | | | | (1,578,405 | ) | |||||||||||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS |
$ | (2,591,304 | ) | $ | 6,402,940 | $ | 12,919,250 | $ | (19,322,190 | ) | $ | (2,591,304 | ) |
For the year ended December 31, 2013 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES |
||||||||||||||||||||||
Net income
(loss) |
$ | (194,955 | ) | $ | 17,129,258 | $ | 18,039,669 | $ | (35,168,927 | ) | $ | (194,955 | ) | |||||||||
Adjustments to
reconcile net income (loss) to cash flows from operating activities: |
||||||||||||||||||||||
Equity of
subsidiaries |
(17,080,738 | ) | (18,088,189 | ) | | 35,168,927 | | |||||||||||||||
Gain on life
settlements |
| | (39,337,542 | ) | | (39,337,542 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs |
1,908,248 | 823,004 | (260,861 | ) | | 2,470,391 | ||||||||||||||||
Deferred
income taxes |
2,173,767 | | | | 2,173,767 | |||||||||||||||||
Preferred
stock issued for dividends |
623,899 | | | | 623,899 | |||||||||||||||||
Convertible,
redeemable preferred stock dividends payable |
255 | | | | 255 | |||||||||||||||||
Gain upon
termination of agreement with Athena Securities Ltd. |
(3,252,400 | ) | | | | (3,252,400 | ) | |||||||||||||||
(Increase)
decrease in operating assets: |
||||||||||||||||||||||
Due from
related parties |
| 8,613 | | | 8,613 | |||||||||||||||||
Death
benefits receivable |
| | 2,850,000 | | 2,850,000 | |||||||||||||||||
Other assets
|
(51,522,808 | ) | (45,077,218 | ) | | 96,033,606 | (566,420 | ) | ||||||||||||||
Increase
(decrease) in operating liabilities: |
||||||||||||||||||||||
Accounts
payable |
160,130 | 1,680 | 208,000 | | 369,810 | |||||||||||||||||
Interest
payable |
2,399,975 | 809,540 | 208,918 | | 3,418,433 | |||||||||||||||||
Other accrued
expenses |
277,321 | (224,990 | ) | (1,690 | ) | | 50,641 | |||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES |
(64,507,306 | ) | (44,618,302 | ) | (18,293,506 | ) | 96,033,606 | (31,385,508 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES |
||||||||||||||||||||||
Investment in
life settlements |
| | (34,997,500 | ) | | (34,997,500 | ) | |||||||||||||||
Proceeds from
settlement of life settlements |
| | 4,563,896 | | 4,563,896 | |||||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES |
| | (30,433,604 | ) | | (30,433,604 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES |
||||||||||||||||||||||
Net proceeds
from revolving credit facility |
| | 8,000,000 | | 8,000,000 | |||||||||||||||||
Payments for
redemption of Series I Secured notes payable |
| (8,671,624 | ) | | | (8,671,624 | ) | |||||||||||||||
Proceeds from
issuance of debentures |
85,260,976 | | | | 85,260,976 | |||||||||||||||||
Payments for
issuance of debentures |
(4,320,542 | ) | | | | (4,320,542 | ) | |||||||||||||||
Payments for
redemption of debentures |
(8,143,363 | ) | | | | (8,143,363 | ) | |||||||||||||||
Proceeds
(payments) from restricted cash |
| 328,700 | (4,068,578 | ) | | (3,739,878 | ) | |||||||||||||||
Issuance of
member capital |
| 51,237,918 | 44,795,688 | (96,033,606 | ) | | ||||||||||||||||
Payments for
redemption of preferred stock |
(613,708 | ) | | | | (613,708 | ) | |||||||||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES |
72,183,363 | 42,894,994 | 48,727,110 | (96,033,606 | ) | 67,771,861 | ||||||||||||||||
NET INCREASE
IN CASH AND CASH EQUIVALENTS |
7,676,057 | (1,723,308 | ) | | | 5,952,749 | ||||||||||||||||
CASH AND
CASH EQUIVALENTS |
||||||||||||||||||||||
BEGINNING OF
THE YEAR |
25,035,579 | 2,461,465 | | | 27,497,044 | |||||||||||||||||
END OF THE
YEAR |
$ | 32,711,636 | $ | 738,157 | $ | | $ | | $ | 33,449,793 |
For the year ended December 31, 2012 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES |
||||||||||||||||||||||
Net income
(loss) |
$ | (1,012,899 | ) | $ | 6,402,940 | $ | 12,919,250 | $ | (19,322,190 | ) | $ | (1,012,899 | ) | |||||||||
Adjustments to
reconcile net income (loss) to cash flows from operating activities: |
||||||||||||||||||||||
Equity of
subsidiaries |
(6,286,492 | ) | (13,035,698 | ) | | 19,322,190 | | |||||||||||||||
Gain on life
settlements |
| | (27,856,374 | ) | | (27,856,374 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs |
506,279 | 1,169,755 | 232,896 | | 1,908,930 | |||||||||||||||||
Deferred
income taxes |
1,193,190 | | | | 1,193,190 | |||||||||||||||||
Preferred
stock issued for dividends |
567,478 | | | | 567,478 | |||||||||||||||||
Convertible,
redeemable preferred stock dividends payable |
338,695 | | | | 338,695 | |||||||||||||||||
(Increase)
decrease in operating assets: |
||||||||||||||||||||||
Due from
related parties |
| (6,348 | ) | | | (6,348 | ) | |||||||||||||||
Death
benefits receivable |
| | (2,850,000 | ) | | (2,850,000 | ) | |||||||||||||||
Other
assets |
(33,137,100 | ) | (22,587,090 | ) | (772,090 | ) | 55,627,115 | (869,165 | ) | |||||||||||||
Increase
(decrease) in operating liabilities: |
||||||||||||||||||||||
Accounts
payable |
(306,373 | ) | 48,665 | | | (257,708 | ) | |||||||||||||||
Interest
payable |
918,374 | 806,058 | 20,167 | | 1,744,599 | |||||||||||||||||
Other accrued
expenses |
(55,890 | ) | (16,352 | ) | 2,950 | | (69,292 | ) | ||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES |
(37,274,738 | ) | (27,218,070 | ) | (18,303,201 | ) | 55,627,115 | (27,168,894 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES |
||||||||||||||||||||||
Investment in
life settlements |
| | (15,067,495 | ) | | (15,067,495 | ) | |||||||||||||||
Proceeds from
settlement of life settlements |
| | 1,067,210 | | 1,067,210 | |||||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES |
| | (14,000,285 | ) | | (14,000,285 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES |
||||||||||||||||||||||
Net proceeds
from revolving credit facility |
| | 11,000,000 | | 11,000,000 | |||||||||||||||||
Payments for
redemption of Series I Secured notes payable |
| (7,477,197 | ) | | | (7,477,197 | ) | |||||||||||||||
Proceeds from
issuance of debentures |
58,553,280 | | | | 58,553,280 | |||||||||||||||||
Payments for
issuance of debentures |
(3,024,545 | ) | | | | (3,024,545 | ) | |||||||||||||||
Payments for
redemption of debentures |
(112,500 | ) | | | | (112,500 | ) | |||||||||||||||
Proceeds
(payments) from restricted cash |
| (926,473 | ) | 3,627,683 | | 2,701,210 | ||||||||||||||||
Issuance of
member capital |
| 37,951,312 | 17,675,803 | (55,627,115 | ) | | ||||||||||||||||
Issuance of
preferred stock |
6,414,273 | | | | 6,414,273 | |||||||||||||||||
Payments for
issuance of preferred stock |
(1,266,647 | ) | | | | (1,266,647 | ) | |||||||||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES |
60,563,861 | 29,547,642 | 32,303,486 | (55,627,115 | ) | 66,787,874 | ||||||||||||||||
NET INCREASE
IN CASH AND CASH EQUIVALENTS |
23,289,123 | 2,329,572 | | | 25,618,695 | |||||||||||||||||
CASH AND
CASH EQUIVALENTS |
||||||||||||||||||||||
BEGINNING OF
THE YEAR |
1,746,456 | 131,893 | | | 1,878,349 | |||||||||||||||||
END OF THE
YEAR |
$ | 25,035,579 | $ | 2,461,465 | $ | | $ | | $ | 27,497,044 |
December 31, 2013 |
December 31, 2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
% |
% |
|||||||||
Life
insurance company |
||||||||||
Company A
|
16.58 | 16.96 | ||||||||
Company B
|
11.34 | 13.80 | ||||||||
Company C
|
* | 11.36 |
* |
percentage does not exceed 10% of the total face value. |
December 31, 2013 |
December 31, 2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
% |
% |
|||||||||
State of
residence |
||||||||||
California
|
28.14 | 28.44 | ||||||||
Florida
|
15.59 | 13.27 | ||||||||
New York
|
10.65 | 11.85 |
March 31, 2014 (unaudited) |
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
ASSETS |
||||||||||
Cash and cash
equivalents |
$ | 28,083,299 | $ | 33,449,793 | ||||||
Restricted
cash |
2,853,763 | 5,832,970 | ||||||||
Investment in
life settlements, at fair value |
254,503,535 | 234,672,794 | ||||||||
Other assets
|
2,136,666 | 1,424,919 | ||||||||
TOTAL
ASSETS |
$ | 287,577,263 | $ | 275,380,476 | ||||||
LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||
LIABILITIES |
||||||||||
Revolving
credit facility |
$ | 79,000,000 | $ | 79,000,000 | ||||||
Series I
Secured notes payable |
28,602,238 | 29,275,202 | ||||||||
Renewable
Secured Debentures |
145,989,431 | 131,646,062 | ||||||||
Interest
payable |
8,399,192 | 7,209,408 | ||||||||
Accounts
payable and accrued expenses |
1,293,139 | 1,343,952 | ||||||||
Deferred
taxes, net |
6,720,316 | 7,675,174 | ||||||||
TOTAL
LIABILITIES |
270,004,316 | 256,149,798 | ||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK (par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,478,219 and 3,394,916; liquidation preference of $26,087,000 and $25,462,000, respectively) |
25,036,056 | 24,722,693 | ||||||||
STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||
Common stock
(par value $0.001: shares authorized 210,000,000; shares issued and outstanding is 4,562,000 on both March 31, 2014 and December 31, 2013)
|
4,562 | 4,562 | ||||||||
Additional
paid-in capital |
2,872,076 | 2,942,000 | ||||||||
Accumulated
deficit |
(10,339,747 | ) | (8,438,577 | ) | ||||||
TOTAL
STOCKHOLDERS EQUITY (DEFICIT) |
(7,463,109 | ) | (5,492,015 | ) | ||||||
TOTAL
LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) |
$ | 287,577,263 | $ | 275,380,476 |
Three Months Ended |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
March 31, 2014 |
March 31, 2013 |
||||||||||
REVENUE |
|||||||||||
Gain on life
settlements, net |
$ | 5,516,205 | $ | 8,340,356 | |||||||
Interest and
other income |
7,367 | 167,670 | |||||||||
TOTAL REVENUE
|
5,523,572 | 8,508,026 | |||||||||
EXPENSES |
|||||||||||
Employee
compensation and benefits |
968,746 | 1,937,420 | |||||||||
Legal and
professional fees |
325,298 | 437,290 | |||||||||
Interest
expense |
6,326,548 | 4,467,215 | |||||||||
Other
expenses |
759,008 | 1,033,144 | |||||||||
TOTAL
EXPENSES |
8,379,600 | 7,875,069 | |||||||||
INCOME (LOSS)
BEFORE INCOME TAXES |
(2,856,028 | ) | 632,957 | ||||||||
INCOME TAX
EXPENSE (BENEFIT) |
(954,858 | ) | 565,823 | ||||||||
NET INCOME
(LOSS) |
(1,901,170 | ) | 67,134 | ||||||||
Accretion of
preferred stock to liquidation value |
(125,714 | ) | (257,763 | ) | |||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS |
$ | (2,026,884 | ) | $ | (190,629 | ) | |||||
NET INCOME
(LOSS) PER COMMON SHARE (BASIC AND DILUTED) |
|||||||||||
Net income
(loss) |
$(0.42 | ) | $0.01 | ||||||||
Accretion of
preferred stock to liquidation value |
(0.03 | ) | (0.05 | ) | |||||||
Net loss per
share attributable to common shareholders |
$(0.45 | ) | $(0.04 | ) | |||||||
WEIGHTED
AVERAGE SHARES OUTSTANDING |
|||||||||||
Basic and
diluted |
4,562,000 | 4,994,500 |
Three Months Ended |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
March 31, 2014 |
March 31, 2013 |
||||||||||
CASH FLOWS
FROM OPERATING ACTIVITIES |
|||||||||||
Net income
(loss) |
$ | (1,901,170 | ) | $ | 67,134 | ||||||
Adjustments
to reconcile net income (loss) to net cash flows from operating activities: |
|||||||||||
Life
settlements change in fair value |
(11,358,913 | ) | (11,494,725 | ) | |||||||
Amortization
of deferred financing and issuance costs |
353,657 | 1,093,747 | |||||||||
Deferred
income taxes |
(954,858 | ) | 563,874 | ||||||||
Convertible,
redeemable preferred stock dividends payable |
192,340 | 83,702 | |||||||||
(Increase)
decrease in operating assets: |
|||||||||||
Other assets
|
(251,846 | ) | 551,174 | ||||||||
Increase in
operating liabilities: |
|||||||||||
Accounts
payable and other accrued expenses |
1,277,826 | 1,290,756 | |||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES |
(12,642,964 | ) | (7,844,338 | ) | |||||||
CASH FLOWS
FROM INVESTING ACTIVITIES |
|||||||||||
Investment in
life settlements |
(8,271,203 | ) | (9,913,049 | ) | |||||||
Proceeds from
settlement of life settlements |
| 1,490,000 | |||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES |
(8,271,203 | ) | (8,423,049 | ) | |||||||
CASH FLOWS
FROM FINANCING ACTIVITIES |
|||||||||||
Net proceeds
from revolving credit facility |
| 8,000,000 | |||||||||
Payments for
redemption of Series I Secured notes payable |
(868,303 | ) | (1,507,824 | ) | |||||||
Proceeds from
issuance of Renewable Secured Debentures |
18,365,657 | 23,850,794 | |||||||||
Payments for
issuance costs and redemption of Renewable Secured Debentures |
(4,928,888 | ) | (2,303,268 | ) | |||||||
Proceeds
(payments) from restricted cash |
2,979,207 | (4,531,108 | ) | ||||||||
Issuance of
preferred stock |
| (186,669 | ) | ||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES |
15,547,673 | 23,321,925 | |||||||||
NET INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS |
(5,366,494 | ) | 7,054,538 | ||||||||
CASH AND
CASH EQUIVALENTS |
|||||||||||
BEGINNING OF
PERIOD |
33,449,793 | 27,497,044 | |||||||||
END OF
PERIOD |
$ | 28,083,299 | $ | 34,551,582 |
Three Months Ended |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
March 31, 2014 |
March 31, 2013 |
||||||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|||||||||||
Interest and
preferred dividends paid |
$ | 4,250,000 | $ | 3,298,000 | |||||||
NON-CASH
INVESTING AND FINANCING ACTIVITIES |
|||||||||||
Series I
Secured notes: |
|||||||||||
Accrued
interest and commissions payable added to principal |
$ | 65,000 | $ | 61,000 | |||||||
Renewable
Secured Debentures: |
|||||||||||
Accrued
interest and commissions payable added to principal |
$ | 119,000 | 41,000 | ||||||||
Convertible,
redeemable preferred stock: |
|||||||||||
Accretion of
convertible, redeemable preferred stock to redemption value |
$ | 126,000 | $ | 258,000 | |||||||
Conversion of
dividends payable |
$ | 188,000 | $ | 84,000 |
1) |
Receipt of death notice or verified obituary of insured |
2) |
Sale of policy and filing of change of ownership forms and receipt of payment |
As of March 31, 2014 |
As of December 31, 2013 |
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Years Ending December 31, |
Number of Contracts |
Estimated Fair Value |
Face Value |
Number of Contracts |
Estimated Fair Value |
Face Value |
|||||||||||||||||||||
2014 |
| $ | | $ | | | $ | | $ | | |||||||||||||||||
2015 |
4 | 5,238,000 | 6,750,000 | 4 | 5,065,000 | 6,750,000 | |||||||||||||||||||||
2016 |
11 | 10,610,000 | 16,800,000 | 8 | 8,174,000 | 13,750,000 | |||||||||||||||||||||
2017 |
29 | 32,186,000 | 59,916,000 | 25 | 33,345,000 | 63,916,000 | |||||||||||||||||||||
2018 |
30 | 34,573,000 | 71,017,000 | 33 | 37,243,000 | 80,318,000 | |||||||||||||||||||||
2019 |
41 | 43,654,000 | 113,795,000 | 34 | 32,844,000 | 89,295,000 | |||||||||||||||||||||
2020 |
37 | 30,497,000 | 81,014,000 | 34 | 27,741,000 | 75,644,000 | |||||||||||||||||||||
Thereafter |
134 | 97,746,000 | 422,648,000 | 125 | 90,261,000 | 410,975,000 | |||||||||||||||||||||
Totals |
286 | $ | 254,504,000 | $ | 771,940,000 | 263 | $ | 234,673,000 | $ | 740,648,000 |
Three Months Ended: |
March 31, 2014 |
March 31, 2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Change in
fair value |
$ | 11,359,000 | $ | 11,495,000 | ||||||
Premiums and
other annual fees |
(5,843,000 | ) | (5,665,000 | ) | ||||||
Policy
maturities |
| 2,510,000 | ||||||||
Gain on life
settlements, net |
$ | 5,516,000 | $ | 8,340,000 |
Years Ending
December 31, |
||||||
Nine months
ending December 31, 2014 |
$ | 17,882,000 | ||||
2015 |
26,078,000 | |||||
2016 |
28,550,000 | |||||
2017 |
32,109,000 | |||||
2018 |
35,155,000 | |||||
$ | 139,774,000 |
|
Level 1 Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. |
|
Level 2 Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. |
|
Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
2014 |
2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Beginning
balance |
$ | 234,673,000 | $ | 164,317,000 | ||||||
Purchases |
8,472,000 | 10,698,000 | ||||||||
Maturities
(acquisition cost basis) |
| (1,490,000 | ) | |||||||
Gross
unrealized gains |
11,359,000 | 11,616,000 | ||||||||
Gross
unrealized losses |
| (121,000 | ) | |||||||
Ending
balance |
$ | 254,504,000 | $ | 185,020,000 |
As of March 31, 2014 |
As of December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Weighted
average age of insured |
82.3 | 82.1 | ||||||||
Weighted
average life expectancy, months* |
84.3 | 87.0 | ||||||||
Average face
amount per policy |
$ | 2,699,000 | $ | 2,816,000 | ||||||
Discount
rate |
11.69 | % | 11.69 | % |
* |
Standard life expectancy as adjusted for insureds specific circumstances. |
Changes in fair value of life insurance policies |
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Change in life expectancy estimates |
plus 8 months |
minus 8 months |
plus 4 months |
minus 4 months |
|||||||||||||||
March 31,
2014 |
$ | (36,833,000 | ) | $ | 38,756,000 | $ | (18,658,000 | ) | $ | 19,145,000 | |||||||||
December 31,
2013 |
$ | (34,382,000 | ) | $ | 36,152,000 | $ | (17,417,000 | ) | $ | 17,865,000 |
Change in discount rate |
plus 2% |
minus 2% |
plus 1% |
minus 1% |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2014 |
$ | (23,949,000 | ) | $ | 28,161,000 | $ | (12,446,000 | ) | $ | 13,496,000 | ||||||||
December 31,
2013 |
$ | (22,944,000 | ) | $ | 27,063,000 | $ | (11,933,000 | ) | $ | 12,959,000 |
Month issued |
Warrants issued |
Fair value per share |
Risk free rate |
Volatility |
Term |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
December 2011 |
68,937 | $ | 0.22 | 0.42 | % | 25.25 | % | 3 | years | |||||||||||||
March
2012 |
38,130 | $ | 0.52 | 0.38 | % | 36.20 | % | 3 | years | |||||||||||||
June
2012 |
161,841 | $ | 1.16 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
July
2012 |
144,547 | $ | 1.16 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
September 2012 |
2,500 | $ | 0.72 | 0.31 | % | 40.49 | % | 3 | years | |||||||||||||
415,955 |
|
changing its corporate name, offices, and jurisdiction of incorporation |
|
changing any deposit accounts or payment instructions to insurers; |
|
changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect; |
|
merging or consolidating with, or selling all or substantially all of its assets to, any third party; |
|
selling any collateral or creating or permitting to exist any adverse claim upon any collateral; |
|
engaging in any other business or activity than that contemplated by the Agreement; |
|
incurring or guaranteeing any debt for borrowed money; |
|
amending the Companys certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event; |
|
removing an independent director on the board of directors except for cause or with the consent of the lender; or |
|
making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action. |
Years Ending
December 31, |
||||||
Nine months
ending December 31, 2014 |
$ | 8,323,000 | ||||
2015 |
8,638,000 | |||||
2016 |
7,193,000 | |||||
2017 |
4,252,000 | |||||
2018 |
754,000 | |||||
Thereafter |
64,000 | |||||
$ | 29,224,000 |
Years Ending
December 31, |
||||||
Nine months
ending December 31, 2014 |
$ | 31,109,000 | ||||
2015 |
44,587,000 | |||||
2016 |
34,623,000 | |||||
2017 |
13,094,000 | |||||
2018 |
6,779,000 | |||||
Thereafter |
18,873,000 | |||||
$ | 149,065,000 |
|
Up to 33% of the holders unredeemed shares one year after issuance: |
|
Up to 66% of the holders unredeemed shares two years after issuance; and |
|
Up to 100% of the holders unredeemed shares three years after issuance. |
Grant Date |
Exercise Price |
Shares |
Vesting |
Binomial Value |
Forfeiture Factor |
Compensation Expense |
||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/5/2013 | $ | 7.46 | 1,250.00 | Immediate |
0.36 | 0.87 | 391.50 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 142,500.00 | Immediate |
0.36 | 0.87 | 44,631.00 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 25,000.00 | Immediate |
0.36 | 0.87 | 7,830.00 | |||||||||||||||||||
9/5/2013 | $ | 7.46 | 1,500.00 | 1
year |
0.36 | 0.85 | 459.00 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 44,338.50 | 1
year |
0.36 | 0.85 | 13,567.58 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 2,833.50 | 1
year |
0.36 | 0.85 | 867.05 | |||||||||||||||||||
9/5/2013 | $ | 7.46 | 1,500.00 | 2
years |
0.6 | 0.7225 | 650.25 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 44,333.00 | 2
years |
0.6 | 0.7225 | 19,218.36 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 2,833.50 | 2
years |
0.6 | 0.7225 | 1,228.32 | |||||||||||||||||||
9/5/2013 | $ | 7.46 | 1,500.00 | 3
years |
0.82 | 0.6141 | 755.34 | |||||||||||||||||||
9/5/2013 | $ | 7.52 | 44,328.50 | 3
years |
0.82 | 0.6141 | 22,322.15 | |||||||||||||||||||
9/5/2013 | $ | 8.28 | 2,833.00 | 3
years |
0.82 | 0.6141 | 1,426.59 | |||||||||||||||||||
9/30/2013 | $ | 7.52 | 4,000.00 | Immediate |
0.66 | 0.87 | 2,296.80 | |||||||||||||||||||
10/28/2013 | $ | 7.52 | 4,250.00 | Immediate |
0.66 | 0.87 | 2,440.35 | |||||||||||||||||||
10/28/2013 | $ | 7.52 | 17,000.00 | 1
year |
0.66 | 0.85 | 9,537.00 | |||||||||||||||||||
10/28/2013 | $ | 7.52 | 17,000.00 | 2
years |
0.92 | 0.7225 | 11,299.90 | |||||||||||||||||||
10/28/2013 | $ | 7.52 | 12,750.00 | 3
years |
1.14 | 0.6141 | 8,925.94 | |||||||||||||||||||
11/11/2013 | $ | 7.52 | 4,167.00 | 1
year |
0.66 | 0.85 | 2,337.69 | |||||||||||||||||||
11/11/2013 | $ | 7.52 | 4,166.50 | 2
years |
0.92 | 0.7225 | 2,769.47 | |||||||||||||||||||
11/11/2013 | $ | 7.52 | 4,166.50 | 3
years |
1.14 | 0.6141 | 2,916.86 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 1,750.00 | Immediate |
0.66 | 0.87 | 1,004.85 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 7,000.00 | 1
year |
0.66 | 0.85 | 3,927.00 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 7,000.00 | 2
years |
0.92 | 0.7225 | 4,652.90 | |||||||||||||||||||
11/12/2013 | $ | 7.52 | 5,250.00 | 3
years |
1.14 | 0.6141 | 3,675.39 | |||||||||||||||||||
12/12/2013 | $ | 7.52 | 30,000.00 | Immediate |
0.66 | 0.87 | 17,226.00 | |||||||||||||||||||
433,250.00 |
Vested |
Un-vested |
Total |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance as of
December 31, 2013 |
195,000 | 210,250 | 405,250 | |||||||||||
Granted
during the year |
| | | |||||||||||
Exercised
during the year |
| | | |||||||||||
Forfeited
during the year |
(10,000 | ) | (14,750 | ) | (24,750 | ) | ||||||||
Expired
during the year |
| | | |||||||||||
Balance as of
March 31, 2014 |
185,000 | 195,500 | 380,500 |
Nine months
ending December 31, 2014 |
78,000 | |||||
2015 |
70,000 | |||||
Total |
$ | 148,000 |
March 31, 2014 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS |
||||||||||||||||||||||
Cash and cash
equivalents |
$ | 26,466,468 | $ | 1,616,831 | $ | | $ | | $ | 28,083,299 | ||||||||||||
Restricted
cash |
| 350,000 | 2,503,763 | | 2,853,763 | |||||||||||||||||
Investment in
life settlements, at fair value |
| | 254,503,535 | | 254,503,535 | |||||||||||||||||
Other
assets |
395,201 | 723,040 | 1,018,425 | | 2,136,666 | |||||||||||||||||
Investment in
subsidiaries |
148,405,194 | 177,845,326 | | (326,250,520 | ) | | ||||||||||||||||
TOTAL
ASSETS |
$ | 175,266,863 | $ | 180,535,197 | $ | 258,025,723 | $ | (326,250,520 | ) | $ | 287,577,263 | |||||||||||
LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
LIABILITIES |
||||||||||||||||||||||
Revolving
credit facility |
$ | | $ | | $ | 79,000,000 | $ | | $ | 79,000,000 | ||||||||||||
Series I
Secured notes payable |
| 28,602,238 | | | 28,602,238 | |||||||||||||||||
Renewable
Secured Debentures |
145,989,431 | | | | 145,989,431 | |||||||||||||||||
Interest
payable |
4,584,861 | 3,143,600 | 670,731 | | 8,399,192 | |||||||||||||||||
Accounts
payable and other accrued expenses |
399,308 | 384,165 | 509,666 | | 1,293,139 | |||||||||||||||||
Deferred
taxes |
6,720,316 | | | | 6,720,316 | |||||||||||||||||
TOTAL
LIABILITIES |
157,693,916 | 32,130,003 | 80,180,397 | | 270,004,316 | |||||||||||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK |
25,036,056 | | | | 25,036,056 | |||||||||||||||||
STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
Member
capital |
| 148,405,194 | 177,845,326 | (326,250,520 | ) | | ||||||||||||||||
Common
stock |
4,562 | | | | 4,562 | |||||||||||||||||
Additional
paid-in capital |
2,872,076 | | | | 2,872,076 | |||||||||||||||||
Accumulated
deficit |
(10,339,747 | ) | | | | (10,339,747 | ) | |||||||||||||||
TOTAL
STOCKHOLDERS EQUITY (DEFICIT) |
(7,463,109 | ) | 148,405,194 | 177,845,326 | (326,250,520 | ) | (7,463,109 | ) | ||||||||||||||
TOTAL
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) |
$ | 175,266,863 | $ | 180,535,197 | $ | 258,025,723 | $ | (326,250,520 | ) | $ | 287,577,263 |
December 31, 2013 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASSETS |
||||||||||||||||||||||
Cash and cash
equivalents |
$ | 32,711,636 | $ | 738,157 | $ | | $ | | $ | 33,449,793 | ||||||||||||
Restricted
cash |
| 1,420,000 | 4,412,970 | | 5,832,970 | |||||||||||||||||
Investment in
life settlements, at fair value |
| | 234,672,794 | | 234,672,794 | |||||||||||||||||
Other
assets |
381,883 | 484,510 | 558,526 | | 1,424,919 | |||||||||||||||||
Investment in
subsidiaries |
129,839,241 | 159,798,490 | | (289,637,731 | ) | | ||||||||||||||||
TOTAL
ASSETS |
$ | 162,932,760 | $ | 162,441,157 | $ | 239,644,290 | $ | (289,637,731 | ) | $ | 275,380,476 | |||||||||||
LIABILITIES & STOCKHOLDER S EQUITY (DEFICIT) |
||||||||||||||||||||||
LIABILITIES |
||||||||||||||||||||||
Revolving
credit facility |
$ | | $ | | $ | 79,000,000 | $ | | $ | 79,000,000 | ||||||||||||
Series I
Secured notes payable |
| 29,275,202 | | | 29,275,202 | |||||||||||||||||
Renewable
Secured Debentures |
131,646,062 | | | | 131,646,062 | |||||||||||||||||
Interest
payable |
3,806,820 | 3,065,465 | 337,123 | | 7,209,408 | |||||||||||||||||
Accounts
payable and other accrued expenses |
574,026 | 261,249 | 508,667 | | 1,343,952 | |||||||||||||||||
Deferred
taxes |
7,675,174 | | | | 7,675,174 | |||||||||||||||||
TOTAL
LIABILITIES |
143,702,082 | 32,601,916 | 79,845,800 | | 256,149,798 | |||||||||||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK |
24,722,693 | | | | 24,722,693 | |||||||||||||||||
STOCKHOLDERS EQUITY (DEFICIT) |
||||||||||||||||||||||
Member
capital |
| 129,839,241 | 159,798,490 | (289,637,731 | ) | | ||||||||||||||||
Common
stock |
4,562 | | | | 4,562 | |||||||||||||||||
Additional
paid-in capital |
2,942,000 | | | | 2,942,000 | |||||||||||||||||
Accumulated
deficit |
(8,438,577 | ) | | | | (8,438,577 | ) | |||||||||||||||
TOTAL
STOCKHOLDERS EQUITY (DEFICIT) |
(5,492,015 | ) | 129,839,241 | 159,798,490 | (289,637,731 | ) | (5,492,015 | ) | ||||||||||||||
TOTAL
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) |
$ | 162,932,760 | $ | 162,441,157 | $ | 239,644,290 | $ | (289,637,731 | ) | $ | 275,380,476 |
For the three months ended March 31, 2014 |
Parent |
Guarantor Subsidiary |
Non-Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE |
||||||||||||||||||||||
Contract
servicing fees |
$ | | $ | 966,056 | $ | | $ | (966,056 | ) | $ | | |||||||||||
Gain on life
settlements, net |
| | 5,516,205 | | 5,516,205 | |||||||||||||||||
Interest and
other income |
6,929 | 169,615 | 44 | (169,221 | ) | 7,367 | ||||||||||||||||
TOTAL
REVENUE |
6,929 | 1,135,671 | 5,516,249 | (1,135,277 | ) | 5,523,572 | ||||||||||||||||
EXPENSES |
||||||||||||||||||||||
Origination
and servicing fees |
| | 966,056 | (966,056 | ) | | ||||||||||||||||
Employee
compensation and benefits |
590,584 | 378,162 | | | 968,746 | |||||||||||||||||
Legal and
professional fees |
266,159 | 59,139 | | | 325,298 | |||||||||||||||||
Interest
expense |
4,216,528 | 778,567 | 1,331,453 | | 6,326,548 | |||||||||||||||||
Other
expenses |
421,243 | 325,255 | 181,731 | (169,221 | ) | 759,008 | ||||||||||||||||
TOTAL
EXPENSES |
5,494,514 | 1,541,123 | 2,479,240 | (1,135,277 | ) | 8,379,600 | ||||||||||||||||
INCOME (LOSS)
BEFORE EQUITY IN INCOME OF SUBSIDIARIES |
(5,487,585 | ) | (405,452 | ) | 3,037,009 | | (2,856,028 | ) | ||||||||||||||
EQUITY IN
INCOME OF SUBSIDIARY |
2,631,557 | 3,037,009 | | (5,668,566 | ) | | ||||||||||||||||
NET INCOME
(LOSS) BEFORE INCOME TAXES |
(2,856,028 | ) | 2,631,557 | 3,037,009 | (5,668,566 | ) | (2,856,028 | ) | ||||||||||||||
INCOME TAX
BENEFIT |
(954,858 | ) | | | | (954,858 | ) | |||||||||||||||
NET INCOME
(LOSS) |
$ | (1,901,170 | ) | $ | 2,631,557 | $ | 3,037,009 | $ | (5,668,566 | ) | $ | (1,901,170 | ) |
For the three months ended March 31, 2013 |
Parent |
Guarantor Subsidiary |
Non-Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE |
||||||||||||||||||||||
Contract servicing fees |
$ | | $ | 1,278,102 | $ | | $ | (1,278,102 | ) | $ | | |||||||||||
Gain
on life settlements, net |
| | 8,340,356 | | 8,340,356 | |||||||||||||||||
Interest and other income |
8,091 | 136,569 | 23,010 | | 167,670 | |||||||||||||||||
TOTAL
REVENUE |
8,091 | 1,414,671 | 8,363,366 | 8,508,026 | 8,508,026 | |||||||||||||||||
EXPENSES |
||||||||||||||||||||||
Origination and servicing fees |
| | 1,278,102 | (1,278,102 | ) | | ||||||||||||||||
Employee compensation and benefits |
1,546,702 | 390,718 | | | 1,937,420 | |||||||||||||||||
Legal
and professional fees |
399,523 | 37,767 | | | 437,290 | |||||||||||||||||
Interest expense |
2,321,169 | 907,175 | 1,238,871 | | 4,467,215 | |||||||||||||||||
Other
expenses |
634,155 | 386,490 | 12,499 | | 1,033,144 | |||||||||||||||||
TOTAL
EXPENSES |
4,901,549 | 1,722,150 | 2,529,472 | (1,278,102 | ) | 7,875,069 | ||||||||||||||||
INCOME
(LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES |
(4,893,458 | ) | (307,479 | ) | 5,883,894 | | 632,957 | |||||||||||||||
EQUITY
IN INCOME OF SUBSIDIARY |
5,526,115 | 5,882,414 | | (11,408,529 | ) | | ||||||||||||||||
NET
INCOME BEFORE INCOME TAXES |
632,657 | 5,574,935 | 5,833,894 | (11,408,529 | ) | 632,957 | ||||||||||||||||
INCOME
TAX EXPENSE |
565,523 | 300 | | | 565,823 | |||||||||||||||||
NET
INCOME |
$ | 67,134 | $ | 5,574,635 | $ | 5,833,894 | $ | (11,408,529 | ) | $ | 67,134 |
For the three months ended March 31, 2014 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES |
||||||||||||||||||||||
Net income
(loss) |
$ | (1,901,170 | ) | $ | 2,631,557 | $ | 3,037,009 | $ | (5,668,566 | ) | $ | (1,901,170 | ) | |||||||||
Adjustments to
reconcile net loss to cash: |
||||||||||||||||||||||
(Equity) loss
of subsidiaries |
(2,631,557 | ) | (3,037,009 | ) | | 5,668,566 | | |||||||||||||||
Life
settlements change in fair value |
| | (11,358,913 | ) | | (11,358,913 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs |
847,236 | 166,946 | (660,525 | ) | | 353,657 | ||||||||||||||||
Deferred
income taxes |
(954,858 | ) | | | | (954,858 | ) | |||||||||||||||
Preferred
stock issued for dividends |
192,340 | | | | 192,340 | |||||||||||||||||
(Increase) in
operating assets: |
||||||||||||||||||||||
Other
assets |
(15,947,713 | ) | (15,248,357 | ) | | 30,944,224 | (251,846 | ) | ||||||||||||||
Increase in
operating liabilities: |
||||||||||||||||||||||
Accounts
payable and other accrued expenses |
713,785 | 229,443 | 334,598 | | 1,277,826 | |||||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES |
(19,681,937 | ) | (15,257,420 | ) | (8,647,831 | ) | 30,944,224 | (12,642,964 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES |
||||||||||||||||||||||
Investment in
life settlements |
| | (8,271,203 | ) | | (8,271,203 | ) | |||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES |
| | (8,271,203 | ) | | (8,271,203 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES |
||||||||||||||||||||||
Payments for
redemption of Series I Secured notes payable |
| (868,303 | ) | | | (868,303 | ) | |||||||||||||||
Proceeds from
issuance of debentures |
18,365,657 | | | | 18,365,657 | |||||||||||||||||
Payments for
issuance costs and redemption of Renewable Secured Debentures |
(4,928,888 | ) | | | | (4,928,888 | ) | |||||||||||||||
Proceeds from
restricted cash |
| 1,070,000 | 1,909,207 | | 2,979,207 | |||||||||||||||||
Issuance of
member capital |
| 15,934,397 | 15,009,827 | (30,944,224 | ) | | ||||||||||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES |
13,436,769 | 16,136,094 | 16,919,034 | (30,944,224 | ) | 15,547,673 | ||||||||||||||||
NET INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS |
(6,245,168 | ) | 878,674 | | | (5,366,494 | ) | |||||||||||||||
CASH AND
CASH EQUIVALENTS |
||||||||||||||||||||||
BEGINNING OF
THE PERIOD |
32,711,636 | 738,157 | | | 33,449,793 | |||||||||||||||||
END OF THE
PERIOD |
$ | 26,466,468 | $ | 1,616,831 | $ | | $ | | $ | 28,083,299 |
For the three months ended March 31, 2013 |
Parent |
Guarantor Subsidiary |
Non- Guarantor Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES |
||||||||||||||||||||||
Net
income |
$ | 67,134 | $ | 5,574,635 | $ | 5,833,894 | $ | (11,408,529 | ) | $ | 67,134 | |||||||||||
Adjustments to
reconcile net loss to cash: |
||||||||||||||||||||||
(Equity) loss
of subsidiaries |
(5,526,115 | ) | (5,882,414 | ) | | 11,408,529 | | |||||||||||||||
Life
settlements change in fair value |
| | (11,494,725 | ) | | (11,494,725 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs |
393,477 | 272,505 | 427,765 | | 1,093,747 | |||||||||||||||||
Deferred
income taxes |
563,874 | | | | 563,874 | |||||||||||||||||
Preferred
stock issued for dividends |
83,702 | | | | 83,702 | |||||||||||||||||
(Increase)
decrease in operating assets: |
||||||||||||||||||||||
Other
assets |
(14,274,237 | ) | (10,700,326 | ) | 669,198 | 24,856,539 | 551,174 | |||||||||||||||
Increase in
operating liabilities: |
||||||||||||||||||||||
Accounts
payable and other accrued expenses |
844,042 | 131,527 | 315,187 | | 1,290,756 | |||||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES |
(17,848,123 | ) | (10,604,073 | ) | (4,248,681 | ) | 24,856,539 | (7,844,338 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES |
||||||||||||||||||||||
Investment in
life settlements |
| | (9,913,049 | ) | | (9,913,049 | ) | |||||||||||||||
Proceeds from
settlement of life settlements |
| | 1,490,000 | | 1,490,000 | |||||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES |
| | (8,423,049 | ) | | (8,423,049 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES |
||||||||||||||||||||||
Net proceeds
from revolving credit facility |
| | 8,000,000 | | 8,000,000 | |||||||||||||||||
Payments for
redemption of Series I Secured notes payable |
| (1,507,824 | ) | | | (1,507,824 | ) | |||||||||||||||
Proceeds from
issuance of debentures |
23,850,794 | | | | 23,850,794 | |||||||||||||||||
Payments for
issuance costs and redemption of Renewable Secured Debentures |
(2,303,268 | ) | | | | (2,303,268 | ) | |||||||||||||||
Proceeds
(payments) from restricted cash |
| 1,469,676 | (6,000,784 | ) | | (4,531,108 | ) | |||||||||||||||
Payments for
redemption of preferred stock |
(186,669 | ) | (186,669 | ) | ||||||||||||||||||
NET CASH FLOWS
PROVIDED BY FINANCING ACTIVITIES |
21,360,857 | 14,145,877 | 12,671,730 | (24,856,539 | ) | 23,321,925 | ||||||||||||||||
NET INCREASE IN
CASH AND CASH EQUIVALENTS |
3,512,734 | 3,541,804 | | | 7,054,538 | |||||||||||||||||
CASH AND
CASH EQUIVALENTS |
||||||||||||||||||||||
BEGINNING OF
THE PERIOD |
25,035,579 | 2,461,465 | | | 27,497,044 | |||||||||||||||||
END OF THE
PERIOD |
$ | 28,548,313 | $ | 6,003,269 | $ | | $ | | $ | 34,551,582 |
March 31, 2014 |
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Life insurance company |
% | % | ||||||||
Company A
|
15.98 | 16.58 | ||||||||
Company B
|
11.13 | 11.34 |
March 31, 2014 |
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
State of residence |
% | % | ||||||||
California
|
27.97 | 28.14 | ||||||||
Florida
|
15.38 | 15.59 | ||||||||
New York
|
10.84 | 10.65 |
Securities and
Exchange Commission registration fee |
$3,200 | |||||
FINRA filing
fee |
$5,000 | |||||
NASDAQ listing
fee |
$50,000 | |||||
Accounting
fees and expenses |
$100,000 | |||||
Legal fees and
expenses |
$250,000 | |||||
Transfer agent
and registrar fees |
$ | 30,000 | ||||
Printing
expenses |
$ | 80,000 | ||||
Miscellaneous |
$82,000 | |||||
Total |
$600,000 |
(a) |
Exhibits. The exhibits listed below are filed as a part of this registration statement. |
Exhibit Number |
Description |
|||||
---|---|---|---|---|---|---|
1.1 | Form
of Underwriting Agreement (to be filed by amendment) |
|||||
3.1 | Certificate of Incorporation (2) |
|||||
3.2 | Certificate of Amendment of Certificate of Incorporation (3) |
|||||
3.3 | Certificate of Designations for Series A Convertible Preferred Stock (3) |
|||||
3.4 | Bylaws (2) |
|||||
4.1 | Indenture with Bank of Utah, dated October 19, 2011 (relating to Renewable Secured Debentures) (4) |
|||||
4.2 | Form
of Renewable Secured Debenture (3) |
|||||
4.3 | Form
of Subscription Agreement (relating to Renewable Secured Debentures) (revised November 2013) (11) |
|||||
4.4 | Pledge and Security Agreement by and among GWG Holdings, Inc., GWG Life Settlements, LLC, Jon R. Sabes, Steven F. Sabes, and Bank of Utah,
dated October 19, 2011 (relating to Renewable Secured Debentures) (4) |
|||||
4.5 | Intercreditor Agreement by and among Bank of Utah, and Lord Securities Corporation, dated October 19, 2011 (relating to Renewable Secured
Debentures) (4) |
|||||
4.6 | Amendment No. 1 to Indenture with Bank of Utah, dated December 15, 2011 (relating to Renewable Secured Debentures) (7) |
|||||
4.7 | Amendment No. 1 to Pledge and Security Agreement, dated December 15, 2011 (relating to Renewable Secured Debentures) (7) |
|||||
5.1 | Opinion of Maslon Edelman Borman & Brand, LLP (to be filed by amendment) |
|||||
10.1 | Amended and Restated Credit and Security Agreement with DZ Bank AG Deutsche Zentral-Genossenschaftsbank (as agent), and Autobahn Funding
Company LLC (as lender), dated effective January 25, 2013 (8)* |
|||||
10.2 | Performance Guaranty of GWG Holdings, LLC dated July 15, 2008, delivered in favor of DZ Bank AG Deutsche Zentral-Genossenschaftsbank (as
agent), and Autobahn Funding Company LLC (as lender) (3) |
|||||
10.3 | General Reaffirmation and Modification Agreement dated effective January 29, 2013 delivered in favor of DZ Bank AG Deutsche
Zentral-Genossenschaftsbank (as agent), and Autobahn Funding Company LLC (as lender) (11)** |
Exhibit Number |
Description | ||||||
---|---|---|---|---|---|---|---|
10.4 | Third
Amended and Restated Note Issuance and Security Agreement dated November 1, 2011, with Lord Securities Corporation (as trustee), GWG LifeNotes Trust
(as secured party), and noteholders (11) |
||||||
10.5 | Pledge Agreement dated November 15, 2010, among Jon R. Sabes, Steven F. Sabes, Opportunity Finance, LLC, SFS Trust 1976, SFS Trust 1992
Esther, SFS Trust 1982, Mokeson, LLC (collectively as pledgors), and Lord Securities Corporation (as trustee and pledgee) (3) |
||||||
10.6 | Fourth Amended and Restated Managing Broker-Dealer Agreement with Arque Capital dated effective April 5, 2013 (11)*** |
||||||
10.7 | Amended and Restated Investment Agreement with Insurance Strategies Fund, LLC, dated as of September 3, 2009 (3) |
||||||
10.8 | Addendum No. 1 to Sub-Sublease Agreement effective as of July 14, 2008 by Opportunity Finance, LLC and GWG Life, LLC (6) |
||||||
10.9 | Employment Agreement with Jon R. Sabes, dated June 14, 2011 (5) |
||||||
10.10 | Employment Agreement with Steven F. Sabes, dated June 14, 2011 (5) |
||||||
10.11 | Employment Agreement with Paul A. Siegert, dated June 14, 2011 (5) |
||||||
10.12 | Purchase and Sale Agreement with Athena Securities Group Ltd. and Athena Structured Funds PLC, dated July 11, 2011 (3) |
||||||
10.13 | Shareholders Agreement with respect to Athena Structured Funds PLC, dated July 11, 2011 (3)(12) |
||||||
10.14 | Amendment to Third Amended and Restated Note Issuance and Security Agreement, dated as of November 18, 2013, with Lord Securities Corporation
(as trustee for the GWG LifeNotes Trust) (11) |
||||||
10.15 | Purchase and Sale Agreement among GWG Holdings, Inc., Athena Securities Group Limited and GWG Securities International Public Limited Company,
dated June 28, 2013 (10) |
||||||
10.16 | 2013
Stock Incentive Plan dated March 27, 2013 (9) |
||||||
10.17 | Form
of Stock Option Agreement used under 2013 Stock Incentive Plan (revised June 2014) (15)**** |
||||||
10.18 | Addendum to Third Amended and Restated Managing Broker-Dealer Agreement with Arque Capital dated effective February 28, 2013
(13) |
||||||
10.19 | Employment Agreement with William Acheson, dated May 30, 2014 (15) |
||||||
10.20 | Amendment No. 1 to Amended and Restated Credit and Security Agreement with DZ Bank AG Deutsche Zentral-Genossenschaftsbank and Autobahn
Funding Company LLC, dated May 29, 2014 (15) |
||||||
21 | List
of Subsidiaries (9) |
||||||
23.1 | Consent of Mayer Hoffman McCann P.C. (filed herewith) |
||||||
23.2 | Consent of Baker Tilly Virchow Krause, LLP (filed herewith) |
||||||
23.3 | Consent of Maslon Edelman Borman & Brand, LLP (to be contained within Exhibit 5.1 above) |
||||||
99.1 | Letter from Model Actuarial Pricing Systems, dated April 30, 2014 (1) |
||||||
99.2 | Copy
of First Confidential Draft Registration Statement on Form S-1 Submitted February 12, 2014 (14) |
||||||
99.3 | Copy
of Second Confidential Draft Registration Statement on Form S-1 Submitted March 28, 2014 (14) |
||||||
(1) | Incorporated by reference to Quarterly Report on Form 10-Q for the period ended March 31, 2014, filed on May 6, 2014. |
||||||
(2) | Incorporated by reference to Form S-1 Registration Statement filed on June 14, 2011 (File No. 333-174887). |
Exhibit Number |
Description | |||||
---|---|---|---|---|---|---|
(3) | Incorporated by reference to Form S-1/A Registration Statement filed on August 23, 2011 (File No. 333-174887). |
|||||
(4) | Incorporated by reference to Form S-1/A Registration Statement filed on October 20, 2011 (File No. 333-174887). |
|||||
(5) | Incorporated by reference to Form S-1/A Registration Statement filed on September 20, 2011 (File No. 333-174887). |
|||||
(6) | Incorporated by reference to Form S-1/A Registration Statement filed on July 26, 2011 (File No. 333-174887). |
|||||
(7) | Incorporated by reference to Post-Effective Amendment No. 1 to Form S-1/A filed on April 30, 2012 (File No. 333-174887). |
|||||
(8) | Incorporated by reference to Current Report on Form 8-K filed on February 1, 2013. |
|||||
(9) | Incorporated by reference to Annual Report on Form 10-K for the period ended December 31, 2013, filed on March 20, 2014. |
|||||
(10) | Incorporated by reference to Current Report on Form 8-K filed on July 8, 2013. |
|||||
(11) | Incorporated by reference to Post-Effective Amendment No. 8 to Form S-1/A filed on November 12, 2013 (File No. 333-174887). |
|||||
(12) | Agreement was terminated effective June 28, 2013. |
|||||
(13) | Incorporated by reference to Post-Effective Amendment No. 6 to Form S-1/A filed on April 4, 2013 (File No. 333-174887). |
|||||
(14) | Incorporated by reference to Form S-1 Registration Statement filed on April 25, 2014 (File No. 333-195505). |
|||||
(15) | Incorporated by reference to Amendment No. 1 to Form S-1/A Registration Statement filed on June 6, 2014 (File No.
333-195505). |
|||||
* | The
registrant has earlier filed the original Credit and Security Agreement dated July 15, 2008, Consent and Amendment No. 1 to the Credit and Security
Agreement dated December 14, 2010, and Consent and Amendment No. 2 to the Credit and Security Agreement dated June 10, 2011. These documents were filed
as Exhibits 10.1, 10.2 and 10.3, respectively, to the Form S-1/A Registration Statement filed on August 23, 2011. |
|||||
** | The
registrant has earlier filed a Reaffirmation of Guaranty dated as of June 10, 2011, which was filed as Exhibit 10.7 to the Form S-1/A Registration
Statement filed on August 23, 2011. |
|||||
*** | The
registrant has earlier filed a Managing Broker-Dealer Agreement dated August 14, 2011, an amended Managing Broker-Dealer Agreement dated October 19,
2011, an Amended and Restated Managing Broker-Dealer Agreement dated November 16, 2011, and a Second Amended and Restated Managing Broker-Dealer
Agreement dated effective as of November 16, 2011. These documents were filed as Exhibits 10.8 to the Form S-1/A Registration Statements filed on
August 23, October 20, November 28 and December 15, 2011, respectively. |
|||||
**** | The
registrant has earlier filed a Form of Stock Option Agreement for use under the 2013 Stock Incentive Plan, which was filed as Exhibit 10.17 to the
registrants Annual Report on Form 10-K filed on March 20, 2014. |
GWG
Holdings, INC. |
||||||||||
By: |
/s/ Jon R. Sabes |
|||||||||
Chief
Executive Officer |
Name |
Title |
|||||
---|---|---|---|---|---|---|
/s/ Jon R. Sabes |
Director, Chief Executive Officer |
|||||
Jon R.
Sabes |
(Principal Executive Officer) |
|||||
/s/ Paul A. Siegert* |
Director, Executive Chairman |
|||||
Paul A.
Siegert |
||||||
/s/ William Acheson |
Chief
Financial Officer |
|||||
William
Acheson |
(Principal Financial and Accounting Officer) |
|||||
/s/ Steven F. Sabes* |
Director, President and Secretary |
|||||
Steven F.
Sabes |
||||||
/s/ David H. Abramson* |
Director |
|||||
David H.
Abramson |
||||||
/s/ Charles H. Maguire III* |
Director |
|||||
Charles H.
Maguire III |
||||||
/s/ Jeffrey L. McGregor* |
Director |
|||||
Jeffrey L.
McGregor |
Exhibit Number |
Description |
|||||
---|---|---|---|---|---|---|
23.1 | Consent of Mayer Hoffman McCann P.C. |
|||||
23.2 | Consent of Baker Tilly Virchow Krause, LLP |